---
document_datetime: 2024-10-23 11:25:05
document_pages: 60
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/edurant-h-c-002264-x-0042-g-epar-assessment-report_en.pdf
document_name: edurant-h-c-002264-x-0042-g-epar-assessment-report_en.pdf
version: success
processing_time: 49.42242
conversion_datetime: 2025-12-17 09:42:28.38824
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 July 2024 EMA/375172/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report on extension of marketing authorisation

Edurant

Rilpivirine

Procedure No. EMEA/H/C/002264/X/0042/G

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................6                              |                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................      | 6                                                                                                         |
| 1.2. Legal basis, dossier content.................................................................................      | 6                                                                                                         |
| 1.3. Information on Paediatric requirements.................................................................            | 6                                                                                                         |
| 1.4. Information relating to orphan market exclusivity                                                                  | ................................................... 6                                                     |
| 1.4.1. Similarity                                                                                                       | ....................................................................................................... 6 |
| 1.5. Scientific advice................................................................................................. | 7                                                                                                         |
| 1.6. Steps taken for the assessment of the product                                                                      | ....................................................... 7                                                 |
| 2. Scientific discussion                                                                                                | ................................................................................8                         |
| 2.1. Problem statement.............................................................................................     | 8                                                                                                         |
| 2.1.1. Disease or condition.........................................................................................    | 8                                                                                                         |
| 2.1.2. Epidemiology                                                                                                     | .................................................................................................. 8      |
| 2.1.3. Biologic features..............................................................................................  | 9                                                                                                         |
| 2.1.4. Clinical presentation, diagnosis..........................................................................       | 9                                                                                                         |
| 2.1.5. Management...................................................................................................    | 9                                                                                                         |
| 2.2. About the product                                                                                                  | ............................................................................................ 10           |
| 2.3. Type of Application and aspects on development ..................................................                  | 10                                                                                                        |
| 2.4. Quality aspects ................................................................................................   | 11                                                                                                        |
| 2.4.1. Introduction                                                                                                     | ................................................................................................. 11      |
| 2.4.2. Active Substance...........................................................................................      | 11                                                                                                        |
| 2.4.3. Finished Medicinal Product ..............................................................................        | 11                                                                                                        |
| Description of the product and Pharmaceutical development.........................................                      | 11                                                                                                        |
| Manufacture of the product and process controls.........................................................                | 13                                                                                                        |
| Product specification ...............................................................................................   | 13                                                                                                        |
| Stability of the product............................................................................................    | 14                                                                                                        |
| Adventitious agents ................................................................................................    | 14                                                                                                        |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects.............................                       | 14                                                                                                        |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ..................... 14                                                                                  |
| 2.4.6. Recommendations for future quality development ..............................................                    | 15                                                                                                        |
| 2.5. Non-clinical aspects..........................................................................................     | 15                                                                                                        |
| 2.5.1. Ecotoxicity/environmental risk assessment........................................................                | 15                                                                                                        |
| 2.5.2. Discussion on non-clinical aspects....................................................................           | 15                                                                                                        |
| 2.5.3. Conclusion on the non-clinical aspects..............................................................             | 15                                                                                                        |
| 2.6. Clinical aspects                                                                                                   | ................................................................................................ 15       |
| 2.6.1. Introduction                                                                                                     | ................................................................................................. 15      |
| 2.6.2. Clinical pharmacology ....................................................................................       | 15                                                                                                        |
| 2.6.3. Discussion on clinical pharmacology .................................................................            | 21                                                                                                        |
| 2.6.4. Conclusions on clinical pharmacology                                                                             | ............................................................... 21                                        |
| 2.6.5. Clinical efficacy                                                                                                | ............................................................................................. 21          |
| 2.6.6. Discussion on clinical efficacy                                                                                  | .......................................................................... 37                             |
| 2.6.7. Conclusions on the clinical efficacy...................................................................          | 39                                                                                                        |
| 2.6.8. Clinical safety ...............................................................................................  | 39                                                                                                        |
| 2.6.9. Discussion on clinical safety                                                                                    | ............................................................................ 49                           |

<div style=\"page-break-after: always\"></div>

| 2.6.10. Conclusions on the clinical safety ...................................................................         | 49                                                                            |
|------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| 2.7. Risk Management Plan......................................................................................        | 49                                                                            |
| 2.7.1. Safety concerns ............................................................................................    | 49                                                                            |
| The MAH proposed the following summary of safety concerns in the RMP: ......................                           | 49                                                                            |
| 2.7.2. Pharmacovigilance plan..................................................................................        | 50                                                                            |
| Summary of planned additional PhV activities from RMP...............................................                   | 50                                                                            |
| Overall conclusions on the PhV Plan                                                                                    | .......................................................................... 51 |
| 2.7.3. Risk minimisation measures............................................................................          | 51                                                                            |
| Routine Risk Minimisation Measures ..........................................................................          | 52                                                                            |
| Additional risk minimisation measures .......................................................................          | 52                                                                            |
| Overall conclusions on risk minimisation measures ......................................................               | 52                                                                            |
| 2.7.4. Conclusion....................................................................................................  | 52                                                                            |
| 2.8. Pharmacovigilance............................................................................................     | 52                                                                            |
| 2.8.1. Pharmacovigilance system..............................................................................          | 52                                                                            |
| 2.8.2. Periodic Safety Update Reports submission requirements ....................................                     | 52                                                                            |
| 3. Benefit-Risk Balance..............................................................................53                |                                                                               |
| 3.1. Therapeutic Context .........................................................................................     | 53                                                                            |
| 3.1.1. Disease or condition.......................................................................................     | 53                                                                            |
| 3.1.2. Available therapies and unmet medical need .....................................................                | 53                                                                            |
| 3.1.3. Main clinical studies .......................................................................................   | 54                                                                            |
| 3.2. Favourable effects............................................................................................    | 54                                                                            |
| 3.3. Uncertainties and limitations about favourable effects                                                            | ........................................... 55                                |
| 3.4. Unfavourable effects.........................................................................................     | 56                                                                            |
| 3.5. Uncertainties and limitations about unfavourable effects ........................................                 | 56                                                                            |
| 3.6. Effects Table ................................................................................................... | 57                                                                            |
| 3.7. Benefit-risk assessment and discussion ...............................................................            | 57                                                                            |
| 3.7.1. Importance of favourable and unfavourable effects ............................................                  | 57                                                                            |
| 3.7.2. Balance of benefits and risks...........................................................................        | 58                                                                            |
| 3.7.3. Additional considerations on the benefit-risk balance ..........................................                | 59                                                                            |
| 3.8. Conclusions.....................................................................................................  | 59                                                                            |
| 4. Recommendations.................................................................................59                  |                                                                               |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

Abbreviation

Definition

3TC

Lamivudine

ABC

Abacavir

ACTH

adrenocorticotropic hormone

ADHD

Attention-deficit/hyperactivity disorder

ADR

adverse drug reaction

AE

adverse event

AI

Acceptable intake

AIDS

Acquired Immunodeficiency Syndrome

ALT

alanine aminotransferase

API

Active pharmaceutical ingredient

ART

antiretroviral therapy

ARV

Antiretroviral

AST

aspartate aminotransferase

AUC

area under the plasma concentration-time curve

AUC0-24h,ss

area under the plasma concentration-time curve from the time of RPV administration up to 24 hours post dosing at steady-state

BCO

biological cut-off

BIC

Bictegravir

CD

cluster of differentiation

CHMP

Committee for Medicinal Products for Human use

CL

Clearance

Cmax

maximum plasma concentration at steady-state

Cmin

minimum plasma concentration

CPCA

Carcinogenic potency categorisation approach

CQA

Critical quality attribute

CSR

clinical study report

CYP

cytochrome P450

DAIDS

Division of AIDS

DHEAS

Dehydroepiandrosterone

DTG

Dolutegravir

EACS

European AIDS Clinical Society

EC

European Commission

eGFR

estimated glomerular filtration rate

EU

European Union

FAS

full analysis set

FC

fold change in EC50 values in cell-based assay

FDA

Food and Drug Administration

FOIA

Freedom of Information Act

FSH

follicle-stimulating hormone

FTC

Emtricitabine

GCP

good clinical practice

GGT

gamma-glutamyl transferase

HIV-1

human immunodeficiency virus-1

HPLC

High performance liquid chromatography

HPTN

HIV Prevention Trials Network

IB

Investigator's Brochure

ICH

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

INSTI

integrase strand transfer inhibitor

KF

Karl Fischer titration

LH

luteinizing hormone

MO

Major objection

NNRTI

non-nucleoside reverse transcriptase inhibitor

N(t)RTI

nucleoside/nucleotide reverse transcriptase inhibitor

OD

Once daily

PD

pharmacodynamic(s)

Ph. Eur.

European Pharmacopoeia

PI

prediction interval

PK

Pharmacokinetic(s)

PMTCT

prevention of mother to-child transmission

popPK

population PK

PSUR

periodic safety update report

PT

preferred term

Q

intercompartmental flow

QC

Quality control

QTPP

Quality target product profile

RAM

resistance-associated mutation

RH

Relative humidity

RPV

Rilpivirine

SAE

serious adverse event

SD

standard deviation

SE

standard error

SmPC

Summary of product characteristics

SOC

system organ class

(S)VF

(suspected) virologic failure

TAF

tenofovir alafenamide

TDF

tenofovir disoproxil fumarate

TSE

Transmissible spongiform encephalopathy

TTC

Threshold of toxicological concern

UNAIDS

Joint United Nations Programme on HIV/AIDS

US(A)

United States (of America)

UV

Ultraviolet

VL

viral load

WHO

World Health Organization

WT

wild type

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

Janssen-Cilag International N.V. submitted on 28 July 2023 a group of variation(s) consisting of extensions of the marketing authorisation and the following variation(s):

| Variation(s) requested   | Variation(s) requested                                                                                                         | Type   |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a                  | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

Extension application to introduce a new pharmaceutical form associated with new strength (2.5 mg dispersible tablets). The new presentation is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in patients ≥2 to &lt;18 years of age and weighing at least 10 kg to less than 25 kg. The PI and RMP have been updated in accordance.

Type II variation (C.I.6.a) to modify the approved therapeutic indication of the already authorised 25 mg film-coated tablets presentation to include, in combination with other antiretroviral medicinal products, treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve and virologically suppressed (HIV-1 RNA less than 50 copies per ml) paediatric patients from 2 to less than 12 years weighing at least 25 kg, based on final results from study TMC278-TiDP38-C213 Cohort 2. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. The updated RMP version 10.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to Annex II and to update the list of local representatives in the Package Leaflet.

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 7.2 of Commission Regulation (EC) No 1234/2008 - Group of variations

## 1.3. Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0101/2022 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0101/2022 was completed.

The PDCO issued an opinion on compliance for the PIP P/0101/2022 eligible for the reward.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition

<div style=\"page-break-after: always\"></div>

related to the proposed indication.

## 1.5. Scientific advice

Please see section 2.3 below on CHMP advice.

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Patrick Vrijlandt Co-Rapporteur:  n/a

The Rapporteur appointed by the PRAC was:

PRAC Rapporteur: Liana Martirosyan

| The application was received by the EMA on                                                                                                                      | 28 July 2023     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                                        | 17 August 2023   |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                    | 6 November 2023  |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                 | n/a              |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                    | 06 Nov 2023      |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                        | 30 Nov 2023      |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                               | 14 December 2023 |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                   | 25 March 2024    |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on | 1 May 2024       |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                        | 16 May 2024      |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the MAH on                                               | 30 May 2024      |
| The MAH submitted the responses to the CHMP List of Outstanding Issues on                                                                                       | 25 June 2024     |
| The CHMP Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                  | 10 July 2024     |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting                 | 25 July 2024     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

The application is intended to extend the current approved EDURANT indication to allow the use of RPV in HIV-1 infected ARV treatment-naïve patients (HIV-1 RNA ≤ 100,000 copies/mL) aged ≥ 2 years and weighing ≥ 10 kg and in virologically suppressed children (HIV-1 RNA &lt;50 copies/mL) aged ≥ 2 to &lt;12 years and weighing ≥ 10 kg. The application consists of both a line extension for a novel 2.5 mg dispersible tablet as well as an extension of indication for the already approved 25 mg film-coated tablet.

The following wording is proposed by the MAH:

## Edurant 25 mg film-coated tablet:

EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and paediatric patients weighing at least 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml (see sections 4.4 and 5.1).

Genotypic resistance testing should guide the use of EDURANT (see sections 4.4 and 5.1).

## Edurant 2.5 mg dispersible tablet:

EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients 2 to less than 18 years of age and weighing at least 14 kg to less than 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml (see sections 4.4 and 5.1).

Genotypic resistance testing should guide the use of EDURANT (see sections 4.4 and 5.1).

## 2.1.2. Epidemiology

HIV continues to be a major global public health issue, having claimed more than 40 million lives so far. In 2022, 630 000 people died from HIV-related causes globally. There were approximately 39 million people living with HIV at the end of 2022, of whom 1.5 million were children 0-14 years old. Since 2010, the number of people acquiring HIV has been reduced, but there were still 1.3 million people becoming newly infected in 2022 globally, 130.000 being children 0-14 years old. (WHO FACT sheet).

There is no cure for HIV infection. However, with access to effective HIV prevention, diagnosis, treatment and care, including for opportunistic infections, HIV infection has become a manageable chronic health condition, enabling people living with HIV to lead long and healthy lives.

<div style=\"page-break-after: always\"></div>

## 2.1.3. Biologic features

HIV-1 infection results in chronic activation of the immune system and a subsequent gradual loss of CD4+ T cells, eventually leading to a state of acquired immunodeficiency (AIDS). One of the predictors for HIV-1 disease progression is the level of HIV-1 RNA in the blood (i.e. viral load). The aim of treatment of HIV-1 infection is therefore to suppress, and subsequently maintain, the HIV-1 viral load to levels that are at least below the limit of detection of most commonly used assays (50 copies/mL of blood).

HIV-1 is a rapidly replicating virus, with an error-prone Reverse Transcriptase (RT). Mutations in the viral genome occur randomly when the virus replicates, with an estimated mutation rate of approximately one nucleotide mutation per replicative cycle. Many HIV variants are simultaneously present in each infected individual, which is also described as 'quasispecies,'. Resistance-associated mutations (RAMs) can rapidly be selected when there is selection pressure due to e.g. too low concentrations of antiviral drugs. Often, resistance to drugs in a certain ARV class results in crossresistance to other drugs in that same class.

## 2.1.4. Clinical presentation, diagnosis

The symptoms of HIV vary depending on the stage of infection. Though people living with HIV tend to be most infectious in the first few months after being infected, many are unaware of their status until the later stages. In the first few weeks after initial infection people may experience no symptoms or an influenza-like illness including fever, headache, rash, or sore throat. As the infection progressively weakens the immune system, they can develop other signs and symptoms, such as swollen lymph nodes, weight loss, fever, diarrhoea, and cough. Without treatment, they could also develop severe illnesses such as tuberculosis, cryptococcal meningitis, severe bacterial infections, and cancers such as lymphomas and Kaposi's sarcoma.

Children may have more rapid disease progression and accelerated damage of the developing immune system compared to adults, with higher viral loads and less effective immunological responses to HIV infection than adults.

## 2.1.5. Management

Standard of care for the treatment of HIV-1 requires use of combination ART to suppress viral replication to below detectable limits, increase CD4 cell counts, and stop disease progression. The choice of the combination regimen depends on the status of the patient, particularly in terms of plasma HIV viral load, CD4 cell counts, any previous treatments and prior treatment failure/intolerance.

Commonly used guidelines are those developed by the WHO, the European AIDS Clinical Society (EACS), the Department of Health and Human Services (DHHS) in the USA and the Paediatric European Network for Treatment of AIDS (PENTA), for use in children and adolescents.

Treatment options in children are more limited compared to adults. The recommended (collaborative Penta/EACS HIV treatment guideline, 2022) initial treatment of HIV-1 infection for paediatric patients is therapy with two NRTIs in combination with a drug from a different class (third agent). DTG is the preferred third agent in all children over 4 weeks of age and 3 kg. Whilst 'preferred options' are recommended, 'alternative options' are acceptable and remain important choices in settings where ART availability is limited or in individuals at particular risk of specific toxicity or DDIs.

<div style=\"page-break-after: always\"></div>

## 2.2. About the product

Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT).

The present application is intended to extend the current approved EDURANT indication to allow the use of RPV in HIV-1 infected ARV treatment-naïve patients (HIV-1 RNA ≤ 100,000 copies/mL) aged ≥ 2 years and weighing ≥ 10 kg and in virologically suppressed children (HIV-1 RNA &lt;50 copies/mL) aged ≥ 2 to &lt;12 years and weighing ≥ 10 kg.

## 2.3. Type of Application and aspects on development

The rilpivirine paediatric development plan has been discussed with European and US Health Authorities. Guidance and advice received has in general been implemented. Table 1 below provides an overview of the interactions for the paediatric development plan that have taken place with EMA.

Table 1. Overview of Health Authority Interactions (EU only)

| Date                                        | Agency   | Subject                           | Major Topics                                                                                                                          |
|---------------------------------------------|----------|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| 19 Jul 2007 (EMEA/H/SA/919/1/2007/III)      | EMEA     | End of Phase Scientific Advice II | Obtain advice on overall development plan, i.e., advice on non-clinical data package in view of initial SA and paediatric development |
| 22 Oct 2009 (EMEA/H/SA/919/1/FU/2/2009/III) | EMEA     | Follow-up Scientific Advice       | Obtain advice onNon-clinical data package in view of initial paediatric development, presentation of Clinical data in the MAA         |
| 2008-2022                                   | EMEA     | PIP                               | Overall pediatric development plan                                                                                                    |

A specific demonstration of antiviral efficacy in paediatric patients is not required (EMEA/CPMP/EWP/633/02 Rev. 3). As it is assumed that the PK/PD relation for a direct acting antiviral is roughly similar regardless of the age of the patient, the efficacy of a dose that yields sufficiently similar exposure in children, compared to adults, would be inferred. The parameters that would be applied to conclude on similarity should be based on available data from the entire development programme, including PK and efficacy data in adults.

In view of this, and in agreement with health authorities, the MAH conducted 2 RPV studies in HIV-1 infected children aged ≥2 to &lt;12 years (Study C213 Cohort 2 in ARV treatment -naïve children aged ≥6 to &lt;12 years with a body weight of ≥17 kg and Study HTX2002 in virologically suppressed children aged ≥2 to &lt;12 years with a body weight of ≥10 kg) to determine the appropriate dose in these paediatric populations, hereby targeting the same exposure as observed in adults, with primary endpoints on PK and tolerability.

To further fulfil regulatory requirements, a total of at least 40 participants was planned to be enrolled in Study C213 Cohort 2 and in Study HTX2002 combined, with at least 12 participants with a body weight of &lt;25 kg, including at least 5 participants with a body weight of &lt;20 kg. Note that initially it was planned to enrol at least 7 participants with a body weight of &lt;20 kg, however, based on regulatory agreement, this number was lowered to 5 participants (Agreed per EU PIP (EMEA-000317PIP01-08-M13, which is also the latest version of the PIP).

<div style=\"page-break-after: always\"></div>

Pursuant to Article 23(2) of Regulation (EC) No 1901/2006, as amended, Janssen-Cilag International NV submitted to the Paediatric Committee on 17 March 2023 a request for verification of compliance with the agreed paediatric investigation plan for the above mentioned medicinal product.

The Paediatric Committee, having reviewed the data submitted in accordance with Article 23 of Regulation (EC) No 1901/2006, is of the opinion, as set out in the appended compliance report, that the measures are in compliance with the agreed above mentioned paediatric investigation plan and that the agreed timelines have been respected accordingly.

## 2.4. Quality aspects

## 2.4.1. Introduction

The new finished product is presented as a dispersible tablet containing 2.5 mg rilpivirine as active substance. The product contains the hydrochloride salt.

Other ingredients are: croscarmellose sodium (E468), lactose monohydrate, mannitol (E421), microcrystalline cellulose (E460), polysorbate 20, povidone K30 (E1201), sodium lauryl sulfate (E487), and sodium stearyl fumarate.

The product is available in Alu-Alu perforated unit dose child-resistant blister with a desiccant integrated in the inner layer and a peelable Alu/Paper lidding foil as described in section 6.5 of the SmPC.

## 2.4.2. Active Substance

## 2.4.2.1. General information

The active substance rilpivirine hydrochloride is already approved for commercial use in Edurant 25 mg, film coated tablet. The new proposed pharmaceutical form contains the same active substance from the same manufacturer. No changes have been made to the currently approved active substance documentation in relation to this line extension.

## 2.4.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

The finished product is a dispersible tablet for oral administration. The tablets are white to almost white, round, 6.5 mm in diameter, and debossed with 'TMC' on one side and 'PED' on the other side.

In line with the agreed paediatric investigation plan for Edurant, the purpose of the finished product development was to develop of an age-appropriate solid oral formulation . The quality target product profile (QTPP) was defined as an ' immediate release tablet for oral suspension, containing rilpivirine hydrochloride equivalent to 2.5 mg of rilpivirine free base for dosing a maximum of 6 tablets a day, enabling a daily dose of 15 mg. The finished product must have a sufficiently low level of impurities and microbial bioburden and have a shelf life of minimum 24 months .' The QTPP informed the identification of critical quality attributes (CQAs) which are each reflected in the release and shelf-life specifications.

<div style=\"page-break-after: always\"></div>

The development of the formulation has been extensively described and all formulation studies from initial concept leading to the selection of the proposed commercial formulation were provided. The choice of a dispersible tablet has also been sufficiently substantiated. The proposed commercial formulation was used in bioavailability and food effect studies and in the pivotal clinical studies conducted in the paediatric population.

The choice and grade of excipients with respect to the characteristics that can influence the finished product performance and manufacturability are adequately discussed and a detailed discussion on the safety as well as on the suitability of each excipient for children in the target age range has been provided for both new and approved formulations. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.4.1 of this report.

In the initial submission, the MAH argued that the formulation had been optimised to ensure control of a genotoxic impurity. However, the CHMP did not agree that the formulation and control strategy were adequate, and the MAH was asked to provide further substantiation as a major objection (MO). In response, the MAH provided data showing that the impurity remains well below 30% of the TTC-based limit at release and shelf-life. The control strategy for this impurity is therefore considered to be adequate and sufficiently justified.

The development of the proposed QC dissolution method has been adequately described and the selected method parameters have been thoroughly justified by experimental data. Justifications for rotation speed, pH and surfactant content were deemed acceptable. The discriminatory power of the method has been demonstrated with respect to relevant parameters.

The description of the manufacturing process development is considered adequate. A detailed discussion on the selection, control, and optimisation of the manufacturing process intended for commercial production batches was provided. For each manufacturing step, the product CQAs that can potentially be impacted by the manufacturing step were identified, and for each CQAs the process parameters that have the potential to impact them are discussed and adequately justified.

Palatability and acceptability of the proposed formulation dispersed in water have been adequately assessed during the pivotal clinical trials. The effect of mixing Edurant 2.5 dispersible tablets with common food and drinks has also been adequately addressed. Compatibility studies were conducted with the following beverages or soft food: water, milk, orange juice and apple sauce. No changes in appearance were observed and compliance with the proposed drug product specifications for assay and chromatographic purity initially and after two hours at room temperature was confirmed. Comparative in vitro dissolution results show that drug release for the preparations with apple sauce, drinking water, orange juice, and sparkling water was similar to the drug release of control. Although the active substance release was significantly faster in milk, the differences observed have adequately justified and the MAH 's conclusion that the faster release profile observed for milk is not expected to impact the pharmacokinetics of the drug is agreed , given that the product must be taken with a meal.

Swallowability of the already-approved 25 mg film-coated tablet was assessed in children in the target population. The majority of the children found the tablet easy to swallow as well as acceptable to take for a longer period of time. Based on these results and taking also into account the size of the tablet, administration of whole 25 mg film-coated tablets to children in the new proposed target population is not expected to be a problem in clinical practice.

The primary packaging is Alu-Alu perforated unit dose child-resistant blister with a desiccant integrated in  the  inner  layer  and  a  peelable  Alu/Paper  lidding  foil.  The  materials  comply  with  Ph.  Eur.  and  EC

<div style=\"page-break-after: always\"></div>

requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The finished product is manufactured at Jansen Cilag S.p.A., Via C. Janssen, Borgo San Michele, Latina, 04100, Italy, which is the currently approved manufacturer for Edurant 25 mg film coated tablets.

The manufacturing process consists of the following steps: blending, granulation, compression into tablets and packaging. The process description as well as the relevant process parameters are consistent with the manufacturing process development data and considered acceptable.

The manufacturing process is considered to be a standard process. Validation will be conducted postapproval but before commercialisation. A process validation scheme has been submitted which is considered satisfactory. Based on the data submitted to date, it is considered that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this type of manufacturing process and pharmaceutical form.

## Product specification

The  finished  product  release  specifications  shown  in Error!  Reference  source  not  found. include appropriate  tests  for  this  kind  of  dosage  form  including  appearance,  identification,  assay,  purity, uniformity of dosage units, dissolution, disintegration, water content, microbial purity, and fineness of dispersion.

In the initial submission, the proposed dissolution limits were not considered acceptable, resulting in a major objection. In response, the MAH tightened the dissolution limits in line with the batches used in pivotal clinical trials. The specifications and applied limits are considered acceptable. Therefore, the major objection was considered to be resolved.

The potential presence of elemental impurities in the finished product has been assessed following a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. Based on the risk assessment it can be concluded that no further elemental impurity controls are needed.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product was submitted considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/MAHs on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). The MAH concluded that there was negligible risk of nitrosamine formation. However, based on the information provided (only the conclusion had been submitted), the CHMP identified the possibility of nitrosamine formation from secondary amines present in the API and trace nitrite potentially present in the excipients, resulting in a major objection.

In response, the MAH provided the requested risk assessment demonstrating that all sources of potential nitrosamine formation had been considered. the MAH provided experimental data showing that potential nitrosamines could not be formed, even under extreme reaction conditions. Therefore, the risk of nitrosamine formation is considered negligible, and no confirmatory testing is required. The major objection was considered to be resolved.

<div style=\"page-break-after: always\"></div>

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards has been presented.

Batch analysis results are provided for development and stability batches and those used in pivotal clinical trials, confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

The finished product is released on the market based on the release specifications, through traditional final product release testing.

## Stability of the product

Stability data from 3 production scale batches of finished product stored for up to 24 months under long term conditions (25 ºC / 60% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. The batches of medicinal product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples were tested for appearance, assay, purity, dissolution, disintegration, water content, microbial purity and fineness of dispersion. The analytical procedures used are stability indicating, as demonstrated by forced degradation studies. No significant changes to any of the measured attributes were observed under long term or accelerated conditions. Photostability carried out according to ICH 1B demonstrates that the product is not photosensitive.

Based on available stability data, the proposed shelf-life of 24 months stored in the original package in order to protect from light and moisture as stated in the SmPC (section 6.3) is acceptable.

## Adventitious agents

It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. The major objections relating to the control strategy for a genotoxic impurity, the limit for the dissolution specification, and the risk of nitrosamines have all been resolved by provision of additional data, justification, or amending the control strategy.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

<div style=\"page-break-after: always\"></div>

## 2.4.6. Recommendations for future quality development

Not applicable.

## 2.5. Non-clinical aspects

## 2.5.1. Ecotoxicity/environmental risk assessment

An updated ERA is not required as this extension of indication is not expected to impact the total environmental exposure.

## 2.5.2. Discussion on non-clinical aspects

The nonclinical information in support of the use of RPV for the treatment of HIV-1 infection in children (≥2 to &lt;12y) was previously submitted to Health Authorities. No new nonclinical studies have been conducted in the current submission. The relevance of the observed RPV effects in animals for the indicated patient population is low.

## 2.5.3. Conclusion on the non-clinical aspects

The Committee agreed that the relevance of the observed RPV effects in animals for the indicated patient population is low.

An updated ERA is not required as this extension of indication is not expected to impact the total environmental exposure.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the MAH

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.6.2. Clinical pharmacology

The newly provided clinical pharmacology data primarily focus on final results from paediatric Studies TMC278-TiDP38-C213 (cohort 2) and TMC278HTX2002 . To dose paediatrics based on body weight, an age-appropriate oral formulation of RPV was developed in the form of dispersible tablets containing rilpivirine hydrochloride equivalent to 2.5 mg of rilpivirine free base, which was investigated in the relative bioavailability study TMC278IFD1008 . RPV PK data in HIV1 infected patients ≥2 to &lt;12 years of age obtained from studies TMC278-TiDP38-C213 (hereafter referred to as Study

<div style=\"page-break-after: always\"></div>

C213) and TMC278HTX2002 (hereafter referred to as Study HTX2002 ) was analysed using a population pharmacokinetic analysis.

The first population PK model, based on data from Study TMC278-TiDP6-C209 and Study TMC278TiDP6-C215 in antiretroviral (ARV)-naïve human immunodeficiency virus (HIV)-1-infected adults in combination with data from ARV-naïve HIV-1infected adolescents (≥12 to &lt;18 years of age) from Cohort 1 of Study C213 , has been further updated by combining data from ARV-naïve HIV-1-infected adolescents (≥12 to &lt;18 years of age) and children (≥6 to &lt;12 years of age) enrolled in Study C213 (Week 48 data cutoff) and virologically suppressed HIV-1infected children (≥2 to &lt;12 years of age) enrolled in Study HTX2002 (Week 24 data cutoff [primary analysis]), with adult intensive pharmacokinetic (PK) data (PK substudies) from Studies C209 and C215 . Furthermore, the population PK model was used to perform exploratory analysis of the relationship between RPV plasma concentrations and delta-QTcF.

## 2.6.2.1. Pharmacokinetics

## Methods - studies C213, HTX2002, and TMC278IFD1008

## Bioanalytical method

In order to quantify RPV in heparin plasma samples, a validated LC-MS/MS method was used. The bioanalytical method was evaluated for accuracy, precision, linearity, sensitivity and range, selectivity, dilution recovery, analyte stability, robustness, ruggedness, and specificity.

The bioanalysis was appropriately validated during study sample analysis. All clinical study samples were analysed within the demonstrated stability period following storage at -20°C. Limited incurred sample reanalysis was performed, nevertheless, validity of the assay was demonstrated in the studies that were submitted during initial marketing application. The ISR results for study HTX2002 had a total passing rate of 100%. No samples were reanalysed in none of the studies. For studies TMC278IFD1008, C213, and HTX2002 , chromatograms of the first 5% of the analysed study samples were included in the bioanalytical study report.

## Pharmacokinetic and statistical analysis

For the three mentioned PK studies, pharmacokinetic parameters were calculated following noncompartmental analysis (NCA). The PK data from the two pediatric PK studies were also added to the popPK modeling (see next section). Pairwise comparisons between different treatments for Cmax, AUC ∞ and AUClast values were based on data in study TMC278IFD1008 . Absence of formulation or food effects was concluded if the 90% CI of AUC and Cmax treatment ratios were within conventional acceptance limits of 80.00% to 125.00%.

For the intensive PK data in studies HTX2002 and C213 , descriptive statistics were used to calculate RPV plasma concentrations at each time point and for the derived PK parameters C0h, Cmax, and AUC24h. Intensive PK samples were collected pre-dose (within 1 hour of RPV intake), and at 2, 4, 5, 6, 9, 12, and 24 hours post-dose. Intensive PK sampling was performed at Week 2 and Week 4 for Study C213 (Cohort 2) and Study HTX2002 , respectively. An optional PK sub-study in Study HTX2002 was performed to collect intensive PK data in participants ≥ 6 years of age with body weight ≥ 25 kg after at least 4 weeks of RPV treatment including at least 2 weeks on 25 mg qd dose. Sparse PK samples were collected at any time at Weeks 2, 4, 8, 12, 24, and 48. The population PK model was updated using sparse PK data from paediatric studies HTX2002 (participants ≥ 2 to &lt;12 years of age) and C213 (participants ≥ 6 to &lt;18 years of age).

<div style=\"page-break-after: always\"></div>

## Population PK analysis in HIV-1-infected paediatric patients

The population PK modelling analysis aimed to quantify the RPV pharmacokinetics and investigate potential differences in the distribution of simulated exposure parameters in paediatric patients ( ≥ 2 to &lt;18 years of age) with respect to the adult target exposure range and to confirm the recommended RPV dosing regimen in paediatrics ( ≥ 2 to &lt;12 years of age).

The overall population PK dataset, which included HIV-1-infected adult patients of studies C209 and C215, adolescent patients of study C213 (cohort 1) and paediatrics patients from additional studies C213 (cohort 2) and HTX2002 . The final population pharmacokinetic model included a total of 127 unique participants with at least one quantifiable sample and a total of 1244 records, including 1205 quantifiable samples, 7 samples (0.56 %) that were BLQ, and 32 samples that were treated as missing and thus deleted. As the amount of BLQ observations was so small, the MAH deleted these observations, which is considered accepted. The final analysis set consisted of 1205 RPV plasma concentrations from 127 participants, of which 4 samples were excluded from the final analysis based on the fact that they were considered outliers.

The final population PK model for oral RPV administration in HIV-1 infected patients was a 2compartment model with absorption described by a lag time followed by a sequential zero- and firstorder absorption, with body weight-based allometric scaling on CL/F, Q/F, and Vc/F. Weight and age were included as time-varying variables. The differences in PK between studies C213 and HTX2002 were described by the additional apparent bioavailability (F1) parameter: F1 = 1.00 for study C213, and F1 = 1.43 for study HTX2002. However, the relative bioavailability of 21% of the dispersible 2.5 mg tablet over the approved 25 mg tablet was not taken into account in the modelling. An additional analysis to assess the effect of the relative bioavailability (Frel) showed that neither using a formulation effect instead of study effect on F1 nor a combined formulation and study effect on F1 resulted in significant improvement (p&gt;0.05), and thus, the formulation effect did not contribute to the explanation of the differences between subjects.

For RPV dose selection in paediatric patients, the model-based simulations for the body weight of 10 to 70 kg in the proposed dose setting (12.5 mg qd for participants with ≥ 10 to &lt;20 kg body weight, 15 mg qd for ≥ 20 to &lt;25 kg, and 25 mg qd for ≥ 25 kg) were performed using the final model. Using body weight for paediatric patients from 10 to 70 kg in 0.2 kg increments, the simulations for 20,000 subjects per each body weight were performed. AUC0-24h,ss, Cmax,ss and C0h,ss were simulated where the F1 parameter represented a 1:1 ratio for both studies.

## Bioavailability

In relative bioavailability study TMC278IFD1008 , the geometric mean ratios and 90% CIs for Cmax, AUC0-last, and AUC0-inf for the selected dispersible tablet were not all found within the 80% to 125% range, indicating that bioavailability between the test products and the reference oral RPV 25 mg tablet are not fully comparable. The bioavailability based on mean AUC0-last was 21% higher for the selected dispersible tablet (mean Cmax was 28% higher, N=15). This difference in bioavailability was taken into account for the proposed posology according to the MAH.

Administration of dispersible tablet formulation under fasted conditions and following yoghurt resulted in a significant lowered exposure (approximately 30%). Orange juice did not seem to affect the bioavailability of the dispersible tablet formulation to a relevant extent, as the point estimates were found within the 80-125% acceptance criteria. The dispersible tablet formulation should be taken with food, in line with oral RPV tablets. Furthermore, dilution of the dispersed tablet using soft food

<div style=\"page-break-after: always\"></div>

(applesauce) or liquids (drinking or sparkling water, milk or orange juice) is not expected to affect the exposure to a clinically relevant extent.

## Pharmacokinetics in paediatric population

Forty-four (44) paediatric participants ≥ 2 to &lt;12 years of age enrolled across Studies C213 and HTX2002 were included in the final population PK analysis, of which 27 participants with a body weight of &gt;25 kg and 17 participants with a body weight of &lt;25 kg were enrolled, including 5 participants with a body weight of &lt;20 kg.

The final population PK model indicated that body weight influenced RPV pharmacokinetics. Differences in exposure between paediatrics, adolescents and adults were primarily driven by differences in body weight. However, this effect was addressed by lowering the dose based on the intensive PK assessment performed after 4 weeks of study treatment, which should translate in a decrease in exposure.

The estimated PK parameters derived from the population PK analysis, which were generally in line with the NCA results, show that plasma exposure in terms of C0h,ss and AUC24h,ss are increased in paediatric patients weighing ≥25 kg compared to adult patients (Table 2).

Table 2. Pharmacokinetic results for rilpivirine after administration of the recommended dosing regimen in paediatric patients versus adults.

RPV Dosea

WeightBand a The 12.5-mg and 15-mg doses were administered as 5 and 6 dispersed 2.5-mg tablets (G009-01), respectively. The 25-mg dose was administered as one 25-mg tablet (marketedformulation).

|                               | PediatricPatients≥2to<18years C213,HTX2002   | PediatricPatients≥2to<18years C213,HTX2002   | PediatricPatients≥2to<18years C213,HTX2002   | Reference,Adults C209,C215   |
|-------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------|
| PharmacokineticsofRPv Mean±SD | 12.5 mg qd ≥10 to <20 kg                     | 15 mgqd ≥20 to <25 kg                        | 25mgqd ≥25 kg                                | 25mgqd                       |
| N                             | 4                                            | 7                                            | 62b                                          | 679c                         |
| AUC24h (ng.h/mL)              | 3,528±1,431d                                 | 3,197±1,051d                                 | 3,004±1,231d                                 | 2,397±1,032e                 |
| Coh (ng/mL)                   | 117±47.0d                                    | 100±41.1d                                    | 100±41.0d                                    | 80.1±36.5e                   |
| Cmax (ng/mL)                  | 207±108f                                     | 201±46.5f                                    | 134±76.18                                    | 134±72.0h                    |

b N=31 for Cmax.

d From popPK analysis in Phase 2 Studies C213 (Cohort 1 and 2, Week 48 analysis) and HTX2002 (Week 48 analysis).

c N=44 for Cmax.

eFrompopPKanalysisinPhase3StudiesC209 andC215(Week48analysis).

From intensive PK analysis in Phase 2 Studies C213(Cohort 1 and 2,Week 48 analysis) and HTX2002 (Week 48 analysis); posthoc analysis(Appendix 2.7.2.6).

f From intensive PK analysis in Phase 2 Studies C213 (Cohort 2, Week 48 analysis) and HTX2002 (Week 48 analysis); posthoc analysis (Appendix 2.7.2.6).

h From intensive PK analysis in Phase 3 Studies C209 and C215 (Week 48 analysis).

AUC24h,ss of paediatric patients ≥25 to &lt;40 kg exceeds the 150% target exposure boundary of the predicted adult geometric mean AUC24h,ss (Figure 1). Furthermore, the C0h,ss of paediatrics ≥25 to &lt;30 kg exceeds the 150% target exposure boundary of the predicted adult geometric mean C0h,ss. The MAH reasoned these increased exposures are not of concern as the 90% prediction interval of Cmax,ss was below the previously derived safety threshold of 750 ng/mL that was established using data from studies TMC278-C131 and TMC278-C152 . QT prolongation versus exposure (ranging from 100% to 300% of the mean Cmax) simulations were performed in order to investigate the chance to observe a negative TQT trial according to ICH E14 (ie, upper bound of the two-sided 90% confidence interval for the QTc effect not exceeding 10 ms) accounting for the inter-trial variability (30% CV) in exposure induced by the finite sample size of such study. These simulations showed that at 185% of mean Cmax of 25 mg (ie, 457 ng/mL), the chance of observing an upper limit of the 90% CI of mean ∆∆QTcF below 10 msec is 80%. The value of mean Cmax of 457 ng/mL was taken as the median of a log-normal distribution with 30% CV, of which the 95th percentile is equal to 749 ng/mL (further rounded to 750 ng/mL). When assuming a 90% chance to observe a negative TQT trial, a mean Cmax threshold of approximately 153% the mean Cmax of 25 mg (ie, 377 ng/mL) and an individual simulated Cmax threshold of approximately 618 ng/mL were simulated. The concentrations in paediatric patients in the

<div style=\"page-break-after: always\"></div>

weight range of ≥25 to &lt;40 kg , with the highest concentration of approximately 315 ng/mL, do not exceed the most conservative safety threshold of 431 ng/mL (see below for more information on how this threshold was established).

Furthermore, the estimated PK parameters indicate that plasma exposure in terms of C0h, Cmax and AUC24h at steady state are increased in paediatric patients weighing &lt; 25 kg compared to adult patients. In paediatric Studies C213 and HTX2002, the enrolled population was comprised of children 5.9 years of age and older, with a body weight of 16.2 kg and higher. Thus, no PK data was available and RPV exposure in virologically suppressed paediatric patients (HIV1 RNA &lt;50 copies/mL) and in treatment-naïve paediatric patients (HIV1 RNA ≤100,000 copies/mL) younger than 5.9 years old and/or with a body weight below 16.2 kg was only simulated using the popPK model (Figure 1). Given that the exposures simulated by this model are exceeding the 150% target range for adult exposure, extension of the indication to paediatric patients below 6 years of age or with a body weight below 16 kg is currently not supported. Therefore, the MAH was requested to further elaborate on the effect of RPV exposures (in terms of AUC24h,ss, C0h,ss and Cmax,ss) in these paediatric patients based on the updated popPK model.The MAH acknowledges the limitations of the included studies to support the extension of indication to patients aged ≥ 2 to &lt;12 years and weighing ≥ 10 kg, and proposes to increase the lower weight limit from 'at least 10 kg' to 'at least 14 kg', and to delete the lower age boundary from the indication. Based on the final PopPK model, the predicted mean AUC in paediatric patients with a body weight of 14 to 16 kg is marginally above 150% of the AUC in adults (ie, specifically 162% at 14 kg), but the upper limit of the 90% prediction interval of Cmax (i.e., 460 ng/mL at 14 kg) is below the safety threshold of 750 ng/mL, calculated based on a 80% chance to observe a negative TQT trial. However, how this threshold was derived was not understood. At D195, the MAH clarified how the safety threshold, i.e. the drug concentration where the upper bound of the two-sided 90% confidence interval for the QTc effect of rilpivirine (according to the concentration-QTC analysis) is equal to 10 ms (at the intersection), was derived. The safety threshold was determined to be 431 ng/mL for females and 1028 ng/mL for males. The upper limit of the 90% prediction interval of Cmax of paediatric patients with a bodyweight of 14 kg exceeds the safety threshold after administration of 12.5 mg RPV when the most conservative safety threshold of 431 ng/mL is assumed. As RPV is administered as 2.5 mg dispersible tablets to paediatric patients within this weight range, a lower dosing regimen could be considered for these paediatric patients which does not exceed the safety threshold. At D195, the MAH provided additional simulations for Cmax and AUC after administration of 10.0 mg RPV. Even though the Cmax is lowered to a concentration that would be preferred, the AUC decreases to an extent that raises uncertainties for the efficacy of RPV as the 5th % prediction interval for AUCss would decrease from 1595 ng.h/mL (12.5 mg) to 1276 ng.h/mL (10 mg) and would drop substantially below the 80% of the target exposure of the predicted adult geometric mean AUC0-24h,ss (i.e., 1666 ng.h/mL). Therefore, even if there would be a small risk of a positive QTc with the dosing regimen of 12.5 mg RPV, this risk outweighs the risk of underexposure. Under-exposure results in resistance development which is a critical issue in the use of HIV drugs. Furthermore, the cut-off of 431 ng/mL is considered conservative since it was derived in female subjects whereas the threshold in male subjects was higher (1028 ng/mL), which further decreases the risk of a positive QTc trial at the current dose in paediatric patients. Altogether, the proposed RPV posology in paediatric patients, the use of 12.5 mg in paediatrics weighing ≥ 14 kg to &lt;20 kg kg weight groups, is considered appropriate.

Therefore, before further assessing the proposed posology of 5×2.5-mg RPV dispersible tablets qd for paediatrics &lt;20 kg , lower RPV doses should be simulated in these paediatrics. Therefore, MAH was requested to simulate alternative, lower dosing regimen to explore whether an acceptable RPV exposure, in terms of both Cmax and AUC, in paediatric patients weighing ≥ 14 kg to &lt; 20 kg could be achieved.

Furthermore, as no paediatric patients below 16.2 kg were included in study HTX2002 , RPV exposures in this weight group were simulated based on additional modelling and simulation. The simulated 95 th

<div style=\"page-break-after: always\"></div>

% PI of Cmax for paediatric patients of 10 years old was 611 ng/mL, and thus exceeds the safety threshold, which supports to increase the lower weight limit of 'at least 10 kg'. Moreover, increasing the lower weight limit to ≥ 14 kg would align with the corresponding WHO weight band for ARVs (ie, 14 to &lt;20 kg) and better reflects the paediatric population included in study HTX2002 . Therefore, increasing the lower weight limit to ≥ 14 kg is acceptable to the CHMP.

Figure 1. Predicted geometric mean and 90% PI of RPV AUC0-24h,ss in paediatric patients weighing 10 to 70 kg compared with 80 to 150% of predicted adult geometric mean for RPV 12.5 mg qd for ≥10 to &lt;20 kg; RPV 15 mg qd for ≥20 to 25 kg; RPV 25 mg qd for ≥25 kg .

<!-- image -->

AdultGeoMean=predicted adult geometric mean (Population PK Analysis 2015); AUCo-24h,ss=area under the plasma concentration-time curve from the time of RPV administration up to 24 hours postdose at steady state; AUCss=area under the plasma concentration-time curve at steady state; C209=TMC278-TiDP6-C209; C215=TMC278-TiDP6-C215; PI=prediction interval; qd=once daily; RPV=rilpivirine.

Shaded colored area and colored solid line are the 90% PI and the geometric mean AUCs for each regimen; solid black line is the adult geometric mean of individual predicted AUCo-24h,ss in adults (2,083 ng.h/mL) (based on pooled data of Studies C209 and C215); dashed black lines represent 80% and 150% of the adult geometric mean AUCo-24h,ss (1,666-3,124 ng.h/mL).

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Rilpivirine is a diarylpyrimidine NNRTI of HIV 1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT).

## Primary and Secondary pharmacology

There are no new PD data within this application.

<div style=\"page-break-after: always\"></div>

Data on drug-drug interactions for RPV in adults can generally be extrapolated to the paediatric population. Genetic differences in PD response cannot be reliably assessed due to the limited size of the studies.

The potential relationship between plasma concentration and effect has been assessed. Overall, virologic response rate in Study C213 at Week 48, defined as achieving a plasma VL &lt;50 copies/mL, was 72.2% (13/18); exposure ranges largely overlapped between responders and non-responders. In Study HTX2002, the relation between PK and these efficacy parameters of interest could not be assessed because all participants responded.

No clear relationship was observed between RPV PK and the occurrence of AEs of interest, QTcF abnormalities, changes in QTcF interval, or changes in laboratory parameters of interest in paediatric Studies C213 and HTX2002.

## 2.6.3. Discussion on clinical pharmacology

Based on the submitted data, there are no new insights in either PD interactions with other medicinal products, genetic differences in PD response, or the relationship between RPV plasma concentration and efficacy or safety parameters.

## 2.6.4. Conclusions on clinical pharmacology

The population PK model sufficiently described the observed data after including body weight-based allometric scaling factors. The PK simulations down to 6 years of age and a body weight of approximately 14 kg are considered acceptable.

## 2.6.5. Clinical efficacy

The clinical data submitted to support the proposed extension of the indication consists of:

- The Week 48 final analysis of the PK, safety/tolerability, and efficacy data of RPV in ARV treatmentnaïve HIV1 infected children aged ≥6 to &lt;12 years (Cohort 2) with a body weight of ≥17 kg from Study C213.
- The Week 24 primary analysis and the Week 48 final analysis of the PK, safety/tolerability, and efficacy data of RPV in virologically suppressed HIV1 infected children aged ≥2 to &lt;12 years with a body weight of ≥10 kg from Study TMC278HTX2002 (referred to as HTX2002).

## 2.6.5.1. Dose response study(ies)

N/A

## 2.6.5.2. Main study(ies)

## Study TMC278-TiDP38-C213-Cohort 2

## Methods

Study C213 is an open-label, single-arm Phase 2 study in ARV treatment-naïve, HIV-1 infected adolescents and children to evaluate the PK, safety, tolerability, and antiviral activity of RPV.

<div style=\"page-break-after: always\"></div>

Cohort 2 evaluated RPV in ARV treatment-naïve, HIV-1 infected children aged ≥ 6 to &lt;12 years and was conducted at multiple sites in the Republic of South Africa, Thailand, and Uganda.

RPV was orally administered qd in combination with an investigator-selected background regimen containing 2 N(t)RTIs.

When 10 participants with intensive PK data [collected at Week 2, irrespective of body weight]) were enrolled and treated for at least 4 weeks in Study C213, an analysis of RPV PK together with shortterm safety and antiviral activity was performed, which was reviewed by the IDMC. Based on the data, the IDMC agreed with the proposed RPV dose of:

- 25 mg RPV for children with a body weight ≥25 kg;
- 15 mg RPV for children with a body weight &lt;25 kg.

The proposed dose recommendation was included in Protocol Amendment 10 of Study C213. An additional analysis of the available PK data (intensive PK [only collected for participants &lt;25 kg] and sparse PK [collected for all participants from week 2 to week 48 throughout the study]) and all available safety, tolerability and antiviral activity/efficacy data from both Study C213 and HTX2002 (virologically suppressed children aged ≥2 to &lt;12 years) were reviewed by the Sponsor and the IDMC to assess the appropriateness of the dose. Based on these results, the following RPV dose recommendations were applied to any new participant recruited in the ongoing paediatric studies:

- RPV 25 mg qd with food for participants with a body weight of ≥25 kg
- RPV 15 mg qd (6×2.5 mg tablets) with food for participants with a body weight of ≥20 to &lt;25 kg
- RPV 12.5 mg qd (5×2.5 mg tablets) with food for participants with a body weight of &lt;20 kg

## Objective(s)

The objectives for Cohort 2 are:

- To evaluate the steady-state PK (based on intensive PK analysis) of RPV 25 mg qd (for participants with a body weight of ≥25 kg), 15 mg qd (for participants with a body weight of &lt;25 kg), or adjusted dose of RPV (qd) in participants aged ≥6 to &lt;12 years
- To evaluate short-term safety, tolerability and antiviral activity/efficacy of RPV in this age group
- To evaluate safety, tolerability and efficacy of RPV over a 48-week treatment period
- To evaluate immunologic changes (as measured by CD4+ cell parameters) over 48 weeks of treatment with RPV
- To assess the evolution of viral genotype and phenotype over 48 weeks of treatment with RPV
- To evaluate PK (by means of population PK) and PK-PD relationships for safety and efficacy of RPV
- To evaluate treatment adherence as measured by the Study Adherence Questionnaire for Children and Teenagers (see protocol Addendum 7).

## Outcomes/endpoints

Primary endpoints are defined as follows:

<div style=\"page-break-after: always\"></div>

- For Part 1 (Week 4):
- o PK parameters (steady-state PK parameters including Cmax, Cmin, AUC24h, Tmax, and CL/F)
- For Part 2 (Week 48):
- o Safety and tolerability of RPV
- o PK parameters based on sparse sampling

Secondary endpoints include the following:

- For Part 1 (Week 4): short-term safety and tolerability of RPV
- For Part 2 (Week 48):
- o Safety parameters (AEs, laboratory parameters [including hematology, biochemistry, and endocrine parameters], vital signs, ECGs and physical examination [including assessment of growth and pubertal development])
- o Plasma viral load at Weeks 4, 12, 24, and 48
- o Resistance determination, including:
-  Real-time testing at screening and at any other visit in case of suspected virologic failure (ie, if HIV RNA ≥200 copies/mL after confirmed HIV RNA &lt;50 copies /mL or in case of lack of response)
-  Plasma-based deep sequencing performed retrospectively at screening and at any other visit in case of suspected virological failure
-  PBMC-based proviral DNA sequencing performed retrospectively at screening and at end of study (ie, upon discontinuation or at Week 48)
- o Change from baseline in CD4+ cell count (cells/μL) and percentage at Week 24 and 48
- o PK-PD relationships for antiviral activity and safety

All enrolled participants (All Enrolled Analysis Set), who received at least 1 dose of RPV will be included in the FAS. The FAS will be used as primary and only population for all analyses; this is also referred to as the All-Participants group.

The efficacy parameters for this study (plasma viral load and CD4+ cell count) were tabulated, analysed descriptively (e.g., n, mean, SD, minimum, median, maximum) and presented graphically. An outcome analysis using the FDA snapshot algorithm was performed.

## Results

## Participant flow

38 ART-naïve, HIV-1 infected children ≥ 6 to &lt;12 years of age were screened, and 18 were enrolled and treated with RPV 25 mg qd (body weight of ≥ 25 kg, or &lt;25 kg if enrolled prior to Protocol Amendment 10), RPV 15 mg qd (body weight of ≥ 20 to &lt;25 kg) or RPV 12.5 mg qd (body weight of &lt;20 kg) in combination with an investigator-selected background regimen of 2 N(t)RTIs.

All 18 participants that were enrolled (All Enrolled Analysis Set), received at least 1 dose of RPV and were included in the FAS.

<div style=\"page-break-after: always\"></div>

Of the 18 participants, 17 (94.4%) participants completed the 48-week treatment period; 1 (5.6%) participant discontinued the study early during the 48-week treatment period due to reaching a virologic endpoint ( Table 3 ). This participant never reached plasma viral load &lt;50 copies/mL. Of the 17 participants who completed the 48-week treatment period, 12 participants entered the post-Week 48 treatment extension of whom 4 participants discontinued the study early during the post-Week 48 treatment extension period due to reaching a virologic endpoint, and the other 8 participants rolled over to Study TMC278IFD3004 after Week 48. Of the 4 participants who discontinued the study early, 1 was a virologic failure at Week 48, and 3 were virologic responders at Week 48 but reported viral load &lt;50 copies/mL at later time points. The remaining 5 participants rolled over to Study TMC278IFD3004 at Week 48.

Table 3. Study disposition: Full Analysis Set

|                                                                             | 12.5 mg qd, <20kg   | 15 mg qd, 20-<25kg   | 25 mg qd, <25kg   | 25 mg qd, >=25kg   | AIlRPV Recommended Dose   | AllParticipants   |
|-----------------------------------------------------------------------------|---------------------|----------------------|-------------------|--------------------|---------------------------|-------------------|
| Analysis set:Full Analysis Set                                              | 2                   | 2                    | 5                 | 9                  | 13                        | 18                |
| Completedparticipationof the48-weekinitial treatment perioda                | 2 (100.0%)          | 2 (100.0%)           | 5 (100.0%)        | 8 (88.9%)          | 12 (92.3%)                | 17 (94.4%)        |
| Terminatedparticipationofthe48-weekinitialtreatment periodprematurely       | 0                   | 0                    | 0                 | 1 (11.1%)          | 1 (7.7%)                  | 1 (5.6%)          |
| Reason fortermination Other*                                                | 0                   | 0                    | 0                 | 1 (11.1%)          | 1 (7.7%)                  | 1 (5.6%)          |
| Completedparticipationofthepostweek48treatment extensionperiod(uptoWeek240) | 0                   | 1 (50.0%)            | 3 (60.0%)         | 4 (44.4%)          | 5 (38.5%)                 | 8 (44.4%)         |
| Terminatedparticipationofthepostweek48treatment extensionperiodprematurely  | 0                   | 0                    | 2 (40.0%)         | 2 (22.2%)          | 2 (15.4%)                 | 4 (22.2%)         |
| Reasonfortermination Subjectreachedavirologicendpoint                       | 0                   | 0                    | 2 (40.0%)         | 2 (22.2%)          | 2 (15.4%)                 | 4 (22.2%)         |

Participants who enrolledin the post week 48 treatment extension period are counted as having completed the 48-week initial treatment period Note:As ofthe study protocolamendment 10,thepost week48treatment extensionperiodof4years was removed forCohort 2participants Rilpivirine dose group is determined by the initial administered dose,inrespective of subsequent dose-alterations. *Reason was reported as reaching a virologic endpoint.

## Recruitment

Study Initiation Date:5 December 2010 (date first participant consented in Cohort 1 of this study; first participant consented in Cohort 2 on 26 May 2016).

Study Completion Date: 16 August 2022 (date of last participant last visit).

The analyses presented in the final report are based on a database lock date of 12 October 2022.

Data Cutoff Date: 16 August 2022.

## Conduct of the study

The protocol has been amended 10 times. The first 5 amendments applied to only Cohort 1 (adolescents ≥ 12 to &lt;18 years of age) and are not described here. The following 5 amendments refer to Cohort 2 (children ≥ 6&lt;12 years of age) which was introduced through Amendment 6 (issued on 8 October 2015). With Amendment 10 (issued on 03 February 2020) the dose recommendations were updated. Based on accumulating data the new dose of 15 mg qd had been selected for the subgroup of participants with a body weight &lt;25 k g. Participants already enrolled before the implementation of this amendment would remain on their original RPV dose of 25 mg qd. An additional analysis of the PK data (intensive and sparse) and all available safety, tolerability and antiviral activity/efficacy data from the current study and Study HTX2002 combined were reviewed by the Sponsor and the IDMC on 16 October 2020 to assess appropriateness of the 15 mg qd dose for participants with a body weight &lt;25kg. This resulted in an RPV dose recommendation of 12.5 mg qd for participants with a body weight &lt;20 kg and 15 mg for participants with body weight between ≥ 20 kg and &lt;25 kg which was communicated to the sites via a Dear Investigator Letter (28 October 2020).

<div style=\"page-break-after: always\"></div>

Major protocol violations were observed in 2/18 (11.1%) participants. One of these participants (in the 25 mg qd [ ≥ 25 kg] dose-weight group) was enrolled but did not satisfy study entry criteria (participant had 1 or more risk factors for QTc prolongation). The other participant (in the 25 mg qd [&lt;25 kg] dose-weight group) was listed as having received wrong treatment or incorrect dose (participant had interruptions of study intervention for 67 days [not consecutive] between baseline and Week 48). This participant had overall suboptimal adherence to RPVl, was a virologic failure post-Week 48, and discontinued the study at Week 84. In addition, several minor protocol deviations occurred due to COVID-19.

## Baseline data

The median age at screening was 9.0 years (range 6 to 11 years). Eight out of 18 (44.4%) participants were in the 6 to &lt;9 -year age group and 10/18 (55.6%) participants in the 9 to &lt;12 -year age group. The median weight at baseline was 25.0 kg (range 17 to 51 kg). Two out of 18 (11.1%) participants weighed &lt;20 kg, 7/18 (38.9%) participants weighed ≥ 20 to &lt;25 kg, and 9/18 (50.0%) participants weighed ≥ 25 kg. (Table 4)

Table 4. Summary of demographic data

|                                         | 12.5 mg qd, <20kg   | 15 mg qd, 20- <25kg   | 25 mg qd, <25kg   | 25 mg qd, >=25kg   | All RPV Recommended Dose   | All Participants   |
|-----------------------------------------|---------------------|-----------------------|-------------------|--------------------|----------------------------|--------------------|
| Analysis set: Full Analysis Set         | 2                   | 2                     | 5                 | 9                  | 13                         | 18                 |
| Sex, n (%)                              |                     |                       |                   |                    |                            |                    |
| N                                       | 2                   | 2                     | 5                 | 9                  | 13                         | 18                 |
| Female                                  | 1 (50.0%)           | 1 (50.0%)             | 2 (40.0%)         | 3 (33.3%)          | 5 (38.5%)                  | 7 (38.9%)          |
| Male                                    | 1 (50.0%)           | 1 (50.0%)             | 3 (60.0%)         | 6 (66.7%)          | 8 (61.5%)                  | 11 (61.1%)         |
| Age (years) at screening                |                     |                       |                   |                    |                            |                    |
| N                                       | 2                   | 2                     | 5                 | 9                  | 13                         | 18                 |
| Mean (SD)                               | 6.0 (0.00)          | 6.5 (0.71)            | 9.2 (0.84)        | 9.4(1.67)          | 8.5 (2.07)                 | 8.7 (1.81)         |
| Median                                  | 6.0                 | 6.5                   | 9.0               | 10.0               | 8.0                        | 9.0                |
| Range                                   | (6; 6)              | (6; 7)                | (8; 10)           | (7; 11)            | (6; 11)                    | (6; 11)            |
| Age (years) (categorical), n (%)        |                     |                       |                   |                    |                            |                    |
| N                                       | 2                   | 2                     | 5                 | 9                  | 13                         | 18                 |
| 6- <9 years                             | 2 (100%)            | 2 (100%)              | 1 (20.0%)         | 3 (33.3%)          | 7 (53.8%)                  | 8 (44.4%)          |
| 9- <12 years                            | 0                   | 0                     | 4(80.0%)          | 6 (66.7%)          | 6 (46.2%)                  | 10 (55.6%)         |
| Race, n (%)                             |                     |                       |                   |                    |                            |                    |
| N                                       | 2                   | 2                     | 5                 | 9                  | 13                         | 18                 |
| Asian                                   | 0                   | 0                     | 1 (20.0%)         | 1 (11.1%)          | 1 (7.7%)                   | 2 (11.1%)          |
| Black or African American               | 2 (100%)            | 2 (100%)              | 4(80.0%)          | 8 (88.9%)          | 12 (92.3%)                 | 16 (88.9%)         |
| Country, n (%)                          |                     |                       |                   |                    |                            |                    |
| N                                       | 2                   | 2                     | 5                 | 9                  | 13                         | 18                 |
| South Africa                            | 0                   | 0                     | 2 (40.0%)         | 5 (55.6%)          | 5 (38.5%)                  | 7 (38.9%)          |
| Thailand                                | 0                   | 0                     | 1 (20.0%)         | 1 (11.1%)          | 1 (7.7%)                   | 2 (11.1%)          |
| Uganda                                  | 2 (100%)            | 2 (100%)              | 2 (40.0%)         | 3 (33.3%)          | 7 (53.8%)                  | 9 (50.0%)          |
| Weight (kg) at baseline                 |                     |                       |                   |                    |                            |                    |
| N                                       | 2                   |                       |                   | 9                  | 13                         | 18                 |
| Mean (SD)                               | 17.0 (0.00)         | 23.5 (1.06)           | 23.6 (0.75)       | 31.4(8.00)         | 28.0 (8.67)                | 26.8 (7.57)        |
| Median                                  | 17.0                | 23.5                  | 24.0              | 30.0               | 27.0                       | 25.0               |
| Range                                   | (17; 17)            | (23; 24)              | (23; 24)          | (26; 51)           | (17; 51)                   | (17; 51)           |
| Weight (categorical) at baseline, n (%) |                     |                       |                   |                    |                            |                    |
| N                                       | 2                   |                       |                   | 9                  | 13                         | 18                 |

<div style=\"page-break-after: always\"></div>

| < 20 kg      |   2 (100%) | 0        | 0        | 0        | 2 (15.4%)   | 2 (11.1%)   |
|--------------|------------|----------|----------|----------|-------------|-------------|
| 20 - < 25 kg |          0 | 2 (100%) | 5 (100%) | 0        | 2 (15.4%)   | 7 (38.9%)   |
| >= 25 kg     |          0 | 0        | 0        | 9 (100%) | 9 (69.2%)   | 9 (50.0%)   |

Key: BMI= Body Mass Index; NAP= Not applicable Note: N = number of participants with data, n = number of participants with that observation Rilpivirine dose group is determined by the initial administered dose, irrespective of subsequent dose-alterations.

RPV Recommended dose: 12.5mg qd for &lt;20kg, 15mg qd for 20 -&lt;25kg, 25mg qd for &gt;=25kg

* Denominator based on number of females

Median duration of known HIV-1 infection was 0.1 years (range 0 to 6 years). The median baseline plasma viral load was 55,400 (range 567-149,000) copies/mL. Four out of 18 (22.2%) participants had a baseline plasma viral load of &gt;100,000 copies/mL but were eligible to enter the study since they had ≤ 100,000 copies/mL at screening. Across all participants, the mean (SD) absolute baseline CD4+ cell count was 597.8 (509.37) cells/μL and the median absolute baseline CD4+ cell count was 432.5 (range 12-2,068) ce lls/μL.

## Numbers analysed

All 18 participants that were enrolled (All Enrolled Analysis Set), received at least 1 dose of RPV and were included in the FAS. The FAS was used as primary and only population for all analyses.

## Outcomes and estimation

Based on the FDA Snapshot algorithm, virologic response (defined as plasma viral load &lt;50 copies/mL) in the All-Participants group at Week 48 was achieved in 13/18 (72.2%) participants, while virologic failure was observed in 3/18 (16.7%) participants. When considering virologic response as plasma viral load &lt;400 copies/mL, 15/18 (83.3%) participants were virologic responders, while 1/18 (5.6%) participant was a virologic failure at Week 48. Two out of 18 (11.1%) participants in the 15 mg qd (20 to ≤ 25 kg) dose group had missing viral load data at Week 48 but remained on study. The latest available viral load for these 2 participants was &lt;50 copies/mL, ie, &lt;20 copies/mL (target not detected) post-Week 48 and 22 copies/mL prior to Week 48, respectively. (Table 5)

Table 5. Virologic Outcome for the 48-week initial treatment period (snapshot approach) by DoseWeight group

|                                                                                      | rilpivinine            | rilpivinine            | rilpivinine                      | rilpivinine             | rilpivinine             | rilpivinine                      |
|--------------------------------------------------------------------------------------|------------------------|------------------------|----------------------------------|-------------------------|-------------------------|----------------------------------|
|                                                                                      | 12.5 mg qd, <20kg      | 15 mg qd, 20-<25kg     | 25 mg qd, <25kg                  | 25 mg qd, >=25kg        | AIIRPV Recommended Dose | All Participants                 |
| Analysis set: Full Analysis Set                                                      | 2                      | 2                      | 5                                | 9                       | 13                      | 18                               |
| Snapshot Outcome(<50 copies/ml）48-week initial treatment period, n(%) (95% CI)       |                        |                        |                                  |                         |                         |                                  |
| N                                                                                    | 2                      | 2                      | 5                                | 9                       | 13                      | 18                               |
| Virologic Response (< 50 copies/mL)                                                  | 1 (50.0%) (1.26;98.74) | 0                      | 4 (80.0%) (28.36;99.49)          | 8 (88.9%) (51.75;99.72) | 9 (69.2%) (38.57;90.91) | 13 (72.2%) (46.52;90.31)         |
| Virologic Failure                                                                    | 1 (50.0%) (1.26;98.74) | 0                      | 1 (20.0%) (0.51;71.64) 1 (20.0%) | 1 (11.1%) (0.28;48.25)  | 2 (15.4%) (1.92;45.45)  | 3 (16.7%) (3.58;41.42) 2 (11.1%) |
| HIV RNA ≥ 50 copies/mL                                                               | 1 (50.0%) (1.26;98.74) | 0                      | (0.51;71.64)                     | 0 0                     | 1 (7.7%) (0.19;36.03) 0 | (1.38;34.71) 0                   |
| Virologicfailure-leadingtodiscontinuation Virologicfailure-discontinued due to other | 0                      | 0                      | 0                                | 1 (11.1%)               | 1 (7.7%)                | 1 (5.6%)                         |
| reason? and last available HIV RNA ≥ 50 copies/mL                                    | 0                      | 0                      | 0                                | (0.28;48.25)            | (0.19;36.03)            | (0.14;27.29)                     |
| Virologicfailure-switchinbackground regimen not permited by theprotocol              | 0                      | 0                      |                                  | 0                       | 0                       | 0                                |
| No viral load data in time window                                                    |                        | 2 (100.0%) (15.81;100) |                                  | 0                       | 2 (15.4%) (1.92;45.45)  | 2 (11.1%) (1.38;34.71)           |
| Missingdataduringwindowbut onstudy                                                   | 0                      | 2 (100.0%) (15.81;100) | 0                                |                         | 2 (15.4%) (1.92;45.45)  | 2 (11.1%) (1.38;34.71)           |
| Discontinueddue tootherreason andlast availableHIVRNA<50copies/mL                    | 0                      | 0                      | 0                                |                         | 0                       | 0                                |
| Discontinueddue toAE/death                                                           |                        | 0                      | 0                                |                         | 0                       | 0                                |

<div style=\"page-break-after: always\"></div>

| SnapshotOutcome(<400copies/ml) ）48-week initial treatment period, n(%) (95% CI)       |                        |                                   |                        |                         |                                  |                                  |
|---------------------------------------------------------------------------------------|------------------------|-----------------------------------|------------------------|-------------------------|----------------------------------|----------------------------------|
| N                                                                                     | 2                      | 2                                 |                        |                         | 13                               | 18                               |
| Virologic Response (< 400 copies/mL)                                                  | 2 (100.0%) (15.81;100) | 0                                 | 5 (100.0%) (47.82;100) | 8 (88.9%) (51.75;99.72) | 10 (76.9%) (46.19;94.96)         | 15 (83.3%) (58.58;96.42)         |
| VirologicFailure                                                                      | 0                      | 0                                 | 0                      | 1 (11.1%) (0.28;48.25)  | 1 (7.7%) (0.19;36.03)            | 1 (5.6%) (0.14;27.29)            |
| HIV RNA ≥400 copies/mL                                                                | 0                      | 0                                 | 0                      | 0                       | 0                                | 0                                |
| Virologicfailure-leadingtodiscontinuation                                             | 0                      | 0                                 | 0                      | 0                       | 0                                | 0                                |
| Virologicfailure-discontinueddue toother reasonandlast availableHIV RNA≥400 copies/mL | 0                      | 0                                 | 0                      | 1 (11.1%) (0.28;48.25)  | 1 (7.7%) (0.19;36.03)            | 1 (5.6%) (0.14;27.29)            |
| Virologic failure - switch in background regimen not permitted by the protocol        | 0                      | 0                                 | 0                      | 0                       | 0                                | 0                                |
| No viral load data in time window                                                     | 0                      | 2 (100.0%) (15.81;100) 2 (100.0%) | 0                      | 0                       | 2 (15.4%) (1.92;45.45) 2 (15.4%) | 2 (11.1%) (1.38;34.71) 2 (11.1%) |
| Missingdataduringwindowbutonstudy                                                     | 0                      | (15.81;100)                       | 0                      | 0                       | (1.92;45.45)                     | (1.38;34.71)                     |
| Discontinuedduetootherreasonandlast availableHIVRNA<400copies/mL                      | 0                      | 0                                 | 0                      | 0                       | 0                                | 0                                |
| DiscontinuedduetoAE/death                                                             | 0                      | 0                                 | 0                      | 0                       | 0                                | 0                                |

Key: CI = Clopper-Pearson confidence interval

Note: N = number of participants with data, n = number of participants with that observation

Rilpivirine dose group is determined by the initial administered dose, irrespective of subsequent dose-alterations.

RPV Recommended dose: 12.5mg qd for &lt;20kg, 15mg qd for 20 -&lt;25kg, 25mg qd for &gt;=25kg a Other reason specified as reaching a virologic endpoint.

Virologic response rate increased until Week 32, with 16/18 (88.9%) participants considered to be virologic responder at that time point, and decreased thereafter.

The mean increase (SE) in CD4+ cell count from baseline was 163.9 (49.16) cells/μL, 304.7 (113.01) cells/μL, and 215.9 (62.42) cells/μL at Weeks 24, 32, and 48, respectively. The mean change from baseline (SE) in CD4% was 6.6 (0.89) at Week 24 and 8.2 (1.44) at Week 48.

For all 18 enrolled participants, standard (PhenoSense) genotypic and phenotypic data were available at screening and baseline. According to the phenotypic analysis at screening and baseline, all 18 participants were susceptible to RPV and all were susceptible to their NRTI backbone regimen. For 8 participants PBMC-based proviral DNA sequencing results were available at screening. One participant with archived NNRTI RAM K101K/Q did not reach undetectable plasma viral load (&lt;50 copies/mL) and withdrew from the study at Week 32. The participant with archived M184I/M at screening had undetectable HIV-1 viral load from Week 12 onwards.

Of the 6 participants with post-baseline standard genotypic data, 2 participants were reported with virologic failure (ie, lack or loss of virologic response), 3 participants met suspected virologic failure criteria only, and 1 participant did not meet (suspected) virologic failure criteria. Five of these participants had available viral load data at baseline: 2 of these participants had a baseline viral load ≥ 100,000 copies/mL of whom 1 also had overall suboptimal adherence; 1 other participant only had overall suboptimal adherence. The 2 participants with suboptimal adherence and post-baseline genotypic data experienced SVF at Week 60 and Week 72, respectively.

Five out of the 6 participants mentioned above had treatment-emergent RPV RAMs (1/2 VFs, 3/3 SVFs, and 1 non-[S]VF) and 4 carried treatment-emergent NRTI RAMs (3/3 SVFs and 1 non-[S]VF). The vast majority of NNRTI and NRTI RAMs observed at screening, Week 48 or early withdrawal, by plasmabased standard sequencing were confirmed using plasma-based deep sequencing. Data obtained retrospectively at Screening and post-Baseline using plasma-based deep sequencing were generally consistent with the results obtained through standard plasma-based or PBMC-based proviral DNA sequencing.

<div style=\"page-break-after: always\"></div>

## Study TMC278HTX2002

## Methods

Study HTX2002 is an open-label, single-arm Phase 2 study in HIV-1 infected, virologically suppressed children aged ≥ 2 to &lt;12 years with a body weight of ≥ 10 kg to evaluate the PK, safety, tolerability, and efficacy of RPV in combination with other ARVs.

Participants received RPV in combination with an investigator-selected background regimen.

The initial RPV dose selected for all participants was 25 mg qd. As of Amendment 2 (18 December 2019) the dose selection of RPV 15 mg qd for participants with a body weight of &lt;25 kg was added. As of Amendment 3 (22 February 2021), this was further updated to an RPV dose of 12.5 mg qd for participants with a body weight &lt;20 kg.

## Objectives

The primary objectives were:

- To evaluate the steady-state pharmacokinetics (PK) of RPV and determine the appropriate dose of RPV in combination with other ARVs in participants aged ≥2 to &lt;12 years with a body weight of &lt;25 kg.
- To evaluate the safety and tolerability of RPV in combination with other ARVs in participants aged ≥2 to &lt;12 years over a 24 -week treatment period.

Secondary objectives were:

- To evaluate the safety and tolerability of RPV in combination with other ARVs over a 48-week treatment period.
- To evaluate the efficacy of RPV in combination with other ARVs over a 24- and 48-week treatment period.
- To evaluate population PK and PK/pharmacodynamic (PD) relationships for safety and efficacy of RPV in combination with other ARVs.
- To assess resistance in case of loss of virologic response to RPV in combination with other ARVs.
- To evaluate treatment adherence to RPV in combination with other ARVs over a 24- and 48week treatment period.

Exploratory objectives were to assess palatability of the 2.5-mg tablet formulation and swallowability of the 25-mg tablet formulation, if applicable. Further, archived viral resistance was to be assessed, if feasible depending on available blood volume.

## Outcomes/endpoints

Primary endpoints related to clinical outcomes:

- Incidence of grade 3/4 adverse events (AEs), serious adverse events (SAEs), HIV-related events (including acquired immune deficiency syndrome [AIDS]-defining illnesses and Stage-3defining Opportunistic Illnesses in HIV Infection), and AEs leading to discontinuation of study intervention through 24 weeks of study treatment.

<div style=\"page-break-after: always\"></div>

Secondary Endpoints related to clinical outcomes included:

- Incidence and severity of AEs/HIV-related events and their relatedness to RPV through 24 and 48 weeks of study treatment.
- Change from baseline over time and shift in toxicity grades/abnormalities versus reference for clinical laboratory parameters, electrocardiogram (ECG) parameters, vital signs, and physical examination through 24 and 48 weeks of study treatment.
- Proportion of participants with HIV1 RNA &lt;50 and ≥50 and &lt;400 and ≥400 copies/mL using the Food and Drug Administration (FDA) Snapshot approach through 24 and 48 weeks of study treatment.
- Immunologic changes, measured by cluster of differentiation (CD)4+ cell count (absolute and percentage relative to total lymphocytes), through 24 and 48 weeks of study treatment.
- Viral genotype at the time of virologic failure through 24 and 48 weeks of study treatment.

The primary analysis (with formal database lock) will be done when all participants have reached Week 24 (or discontinued earlier). The final analysis (with formal database lock) will be done when all participants have reached Week 48 (or discontinued earlier). All statistical analysis will be performed on the intent-to-treat population, defined as all participants who receive at least 1 dose of RPV.

The efficacy parameters for this study (plasma viral load and CD4+ cell count) were tabulated, analysed descriptively (e.g., n, mean, SD, minimum, median, maximum) and presented graphically. An outcome analysis using the FDA snapshot algorithm was performed.

## Results

## Participant flow

Forty participants were screened, and 26 (65.0%) participants were enrolled and treated with RPV (12.5 mg, 15 mg, or 25 mg qd) in combination with the investigator-selected background ARVs. Fourteen (35.0%) participants were screen failures and were not enrolled in the study.

Of the 26 participants enrolled, 1 (3.8%) participant was 2 to &lt;6 years old and 25 (96.2%) participants were 6 to &lt;12 years old. Twenty -three (88.5%) participants completed the Week 48 visit and 3 (11.5%) participants were ongoing at the Week 24 analysis cut-off date. All participants completed the Week 24 visit. None of the participants terminated study participation prematurely ( Table 6 ). Eighteen participants rolled over to Study TMC278IFD3004 after completing Week 48.

Table 6. Study Disposition by Age Group; Full Analysis Set (Study TMC278HTX2002)

|                                         | rilpivirine   | rilpivirine   | rilpivirine      |
|-----------------------------------------|---------------|---------------|------------------|
|                                         | 2 -<6 years   | 6 -<12 yeais  | Al1 Participants |
| Analysis set:Full AnalysisSet           |               | 25            | 26               |
| Participants ongoinga                   | 0             | 3 (12.0%)     | 3 (11.5%)        |
| Completed study participation           | 1 (100.0%)    | 22 (88.0%)    | 23 (88.5%)       |
| Terminatedstudyparticipationprematurely | 0             | 0             | 0                |

a ongoing refers to the 48weeks of treatment

Adapted from:[TSIDS02A.RTF]

[TMC278\\HTX2002\\DBR\\_PA\\_WK24\\RE\\_PA\\_WK24\\PROD\\TSIDS02A.SAS] 09DEC2022,07:23

<div style=\"page-break-after: always\"></div>

Data presented by dose-weight group, are based on the initial dose each participant started with, irrespective of changes in weight-based dosing recommendation (following IDMC analyses) or subsequent individual dose modifications (due to individual weight alterations during the study) ( Table 7 ). All participants who received the 25-mg dose took the single 25-mg tablet formulation.

Table 7. Study Disposition by Dose and Weight Group; Full Analysis Set (Study TMC278HTX2002)

|                                            | rilpivirine       | rilpivirine     | rilpivirine        | rilpivirine       | rilpivirine              | rilpivirine      |
|--------------------------------------------|-------------------|-----------------|--------------------|-------------------|--------------------------|------------------|
|                                            | 12.5 mg qd, <20kg | 15 mg qd, <20kg | 15 mg qd, 20-<25kg | 25 mg qd, >= 25kg | All RPV Recommended Dose | Al1 Participants |
| Analysisset:FullAnalysisSet                | 1                 | 2               | 5                  | 18                | 24                       | 26               |
| Participants ongoing                       | 0                 | 0               | 1 (20.0%)          | 2 (11.1%)         | 3 (12.5%)                | 3 (11.5%)        |
| Completed study participation              | 1 (100.0%)        | 2 (100.0%)      | 4 (80.0%)          | 16 (88.9%)        | 21 (87.5%)               | 23 (88.5%)       |
| Terminated study participation prematurely | 0                 | 0               | 0                  | 0                 | 0                        | 0                |

Note: Rilpivirine dose group is determined by the initial administered dose, inrespective of subsequent dose-alterations. RPV Recommendeddose:12.5mgqdfor&lt;20kg,15mgqdfor20-&lt;25kg,25mgqdfor&gt;=25kg

Adaptedfrom:[TSIDS02B.RTF][TMC278\\HTX2002\\DBRPA\\_WK24\\RE\\_PA\\_WK24\\PROD\\TSIDS02B.SAS]09DEC2022,07:23

## Recruitment

Study Initiation Date:23 July 2019 (date first participant was screened).

Primary Completion Date: 17 August 2022 (last participant last visit/date of last observation from last participant for the Week 24 primary outcome measure as defined in the protocol. Database lock for the primary analysis was 10 October 2022).

Study Completion Date: 17 February 2023 (Date of last participant last visit; Database lock for the final Week 48 analysis: 12 April 2023).

Data Cutoff Date: 17 February 2023 (Date of last observation recorded as part of the database for final analysis).

## Conduct of the study

The protocol has been amended 3 times. Amendment 2 and 3 included changes to the recommended RPV dose. These have been discussed in the Methods section above.

Throughout the study, 2 participants (7.7%) had major protocol deviations . One (3.8%) participant with a body weight &lt;20 kg (in the ≥ 2 to &lt;6 years age group) who was on 12.5 mg RPV did not increase the RPV dose upon increase in body weight to ≥ 20 kg. Body weight in this participant was 20.5 kg at Week 24 and RPV dose was increased to 15 mg, approximately 1 week before the Week 40 visit. The second participant, with a body weight &lt;20 kg (in the ≥ 6 to &lt;12 years age group), started with a higher RPV dose (15 mg instead of 12.5 mg). This participant was switched to 12.5 mg after the first 4 weeks.

## Baseline data

The median age at screening was 9.9 years. One (3.8%) participant was ≥ 2 to &lt;6 years, 8 (30.8%) were ≥ 6 to &lt;9 years, and 17 (65.4%) were ≥ 9 to &lt;12 years. The median weight at baseline was 28.1

<div style=\"page-break-after: always\"></div>

(range 16 to 60) kg. At baseline, 3 (11.5%) participants weighed &lt;20 kg, 5 (19.2%) weighed ≥ 20 to &lt;25 kg, and 18 (69.2%) weighed ≥ 25 kg. ( Table 8 )

Table 8. Summary of Demographics Data by Age Group; Full Analysis Set (Study TMC278HTX2002)

rilpivirine

<!-- image -->

|                                         | 2 -<6 years   |                  | All Participants   |
|-----------------------------------------|---------------|------------------|--------------------|
| Analysis set:Full AnalysisSet           |               | 6 -< 12 years 25 | 26                 |
| Sex,n (%)                               |               |                  |                    |
| N                                       |               | 25               | 26                 |
| Female                                  | 1(100.0%)     | 9 (36.0%)        | 10 (38.5%)         |
| Male                                    | 0             | 16 (64.0%)       | 16 (61.5%)         |
| Age (years) at screening                |               |                  |                    |
| N                                       |               | 25               | 26                 |
| Mean (SD)                               | 5.9 ()        | 9.7 (1.70)       | 9.5 (1.83)         |
| Median                                  | 5.9           | 9.9              | 9.9                |
| Range                                   | (6; 6)        | (6; 12)          | (6; 12)            |
| Age (years) (categorical), n(%)         |               |                  |                    |
| N                                       |               | 25               | 26                 |
| 2-<6 years                              | 1 (100.0%)    | 0                | 1 (3.8%)           |
| 6-<9 years                              | 0             | 8 (32.0%)        | 8 (30.8%)          |
| 9-<12years                              | 0             | 17(68.0%)        | 17 (65.4%)         |
| Race, n (%)                             |               |                  |                    |
| N                                       |               | 25               | 26                 |
| Asian                                   | 0             | 7 (28.0%)        | 7 (26.9%)          |
| Black or African American               | 0             | 13 (52.0%)       | 13 (50.0%)         |
| White                                   | 1(100.0%)     | 5 (20.0%)        | 6 (23.1%)          |
| Country, n (%)                          |               |                  |                    |
| N                                       |               | 25               | 26                 |
| Italy                                   | 1 (100.0%)    | 4 (16.0%)        | 5 (19.2%)          |
| South Africa                            | 0             | 8 (32.0%)        | 8 (30.8%)          |
| Spain                                   | 0             | 3 (12.0%)        | 3 (11.5%)          |
| Thailand                                | 0             | 7 (28.0%)        | 7 (26.9%)          |
| Portugal                                | 0             | 1 (4.0%)         | 1 (3.8%)           |
| Uganda                                  | 0             | 2 (8.0%)         | 2 (7.7%)           |
| Weight (kg) at baseline                 |               |                  |                    |
| N                                       | 1             | 25               | 26                 |
| Mean (SD)                               | 17.5 (-)      | 31.2 (9.60)      | 30.7 (9.78)        |
| Median                                  | 17.5          | 28.9             | 28.1               |
| Range                                   | (18; 18)      | (16; 60)         | (16; 60)           |
| Weight (categorical) at baseline, n (%) |               |                  |                    |
| N                                       |               | 25               | 26                 |
| <20 kg                                  | 1(100.0%)     | 2 (8.0%)         | 3 (11.5%)          |
| 20 -<25kg                               | 0             | 5 (20.0%)        | 5 (19.2%)          |
| >= 25 kg                                | 0             | 18 (72.0%)       | 18 (69.2%)         |

Key:BMI=BodyMassIndex

Note: N = number of participants with data, n = number of participants with that observation

[TSIDEM01A.RTF][TMC278\\HTX2002\\DBR\\_PA\\_WK24\\RE\\_PA\\_WK24\\PROD\\TSIDEM01A.SAS]09DEC2022,07:21

Mode of HIV infection was via mother to child transmission in 24/26 (92.3%) participants, blood transfusion in 1/26 (3.8%) participant, and unknown in 1/26 (3.8%) participant. The median duration of known HIV-1 infection was 7.6 (range 1 to 12) years. The median HIV-1 VL at baseline was 1.0 (range 1 to 125) copy/mL or 0.0 log10 (range 0 log10 to 2 log10) copies/mL. The mean (SD) baseline CD4+ cell count was 874.7 (234.1) cells/µL and the median CD4+ cell count was 881.5 (range 458 to 1,327) cells/ µL.

<div style=\"page-break-after: always\"></div>

Prior ARV therapies were DRV/rtv with RAL and 3TC in the one participant in the 2 to &lt;6 years age group. In the 6 to &lt;12 years age group, 11 participants were on an NNRTI -based regimen (9 on EFV and 2 on NVP), 7 participants were on boosted PIs (6 on LPV/rtv and 1 on DRV/rtv), and 1 was on a DTG-based regimen.

## Numbers analysed

All 26 participants who were enrolled received at least 1 dose of RPV and were included in the FAS. The 2 to &lt;6 years age group had only 1 participant. The FAS was used as the primary and only population for all endpoint analyses.

## Outcomes and estimation

## Virologic outcome

Antiviral activity was assessed based on virologic outcome, ie, virologic response (proportion of participants with plasma HIV1 RNA VL &lt;50 copies/mL and &lt;400 copies/mL) and virologic failure analyzed using the FDA Snapshot algorithm.

At Week 24, 100% of participants remained virologically suppressed (plasma HIV1 RNA VL &lt;50 copies/mL) and none had virologic failure ( Table 9 ).

Table 9. Virologic Outcome at Week 24 (Snapshot analysis) by Age Group; Full Analysis Set (Study TMC278HTX2002)

All

Key: CI=Clopper-Pearson confidence interval Note:N=number ofparticipants with data,n=number ofparticipants with that observation

<!-- image -->

At Week 48, 26/26 (100%) of participants remained virologically suppressed (plasma HIV-1 RNA VL &lt;50 copies/mL) and none had virologic failure.

## Immunology analyses

The mean (SE) change in CD4+ cell count from baseline (analyzed with imputation of last observation carried forward for intermediate missing values) was 37.3 (32.76) cells/mm3 (37.3 [32.76] cells/μL) at Week 24 and -8.4 (29.72) cells/mm3 (-8.4 [29.72] cell s/μL) at Week 48. The mean (SE) increase in the proportion of CD4+ cells (CD4+/lymphocytes) from baseline was 1.4% (1.01%) at Week 24 and 0.9% (1.12%) at Week 48.

## Viral resistance

As no participants met the definition of (S)VF, no standard genotypic resistance data were generated.

Retrospective archived resistance testing data were available for 18 out of 26 (69.2%) participants at screening. ( Table 10 )

<div style=\"page-break-after: always\"></div>

Four participants carried at least 1 archived RPV RAM at screening. The NNRTI RAMs observed among these 4 participants were Y188L, V90I/V+V108I/V+Y181C/I/Y, V179D+Y188L, and E138E/G. In addition, 3 participants carried non-RPV NNRTI RAMs only: 2 had V179I and 1 carried V179I/V. The remaining 11 participants carried no NNRTI RAMs.

There were 3 participants with NRTI RAMs: 1 with M41L only, 1 with V75I/V+Y115F/Y+M184I/M in combination with NNRTI RAMs V90I/V+V108I/V+Y181C/I/Y (mentioned above) and 1 with M184M/V in combination with RT polymorphism V179I (mentioned above).

There were 4 participants with INI RAMs: E138E/K, T97A+R263R/K, S147G/S, and L74M in combination with V179D+Y188L (mentioned above).

The observation of these archived RAMs in a total of 11/18 participants with data, including 4 with RPV RAMs, was not associated with the occurrence of (S)VF as all participants remained virologically suppressed through Week 48.

Table 10. Participants with (pre-) Baseline Genotypic Data by Archived RAMs; Full Analysis Set (Study TMC278HTX2002)

rilpivirine

|                                 | VF   | SVF   | Not(S)VF   | All Participants   |
|---------------------------------|------|-------|------------|--------------------|
| Amalysis set: Full Amalysis Set | 0    | 0     | 26         | 26                 |
| (Pre-) baseline analysis        |      |       |            |                    |
| Nonea                           | 0    | 0     | 8 (30.8%)  | 8 (30.8%)          |
| IAS-USA NRTI at least 1         | 0    | 0     | 3 (11.5%)  | 3 (11.5%)          |
| M1841                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| M184V                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| M41L                            | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| V751                            | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| Y115F                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| Extended NNRTI at least 1       | 0    | 0     | 7 (26.9%)  | 7 (26.9%)          |
| E138G                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| V1081                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| V179D                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| V1791                           | 0    | 0     | 3 (11.5%)  | 3 (11.5%)          |
| 106A                            | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| Y181C                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| Y1811                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| Y188L                           | 0    | 0     | 2 (7.7%)   | 2 (7.7%)           |
| RPV RAM at least 1              | 0    | 0     | 4 (15.4%)  | 4 (15.4%)          |
| E138G                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| Y181C                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| Y1811                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| Y188L                           | 0    | 0     | 2 (7.7%)   | 2 (7.7%)           |
| Integrase RAM at least 1        | 0    | 0     | 4 (15.4%)  | 4 (15.4%)          |
| E138K                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| L74M                            | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| R263K                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| S147G                           | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |
| T97A                            | 0    | 0     | 1 (3.8%)   | 1 (3.8%)           |

Key: RAM= resistance-associated mutation; VF (all)= Virologic failures using all available data up to the database lock

(HIV RNA 2 50 copies/mL)

Note: n = number of participants with that observation

Note: Analysis is based on Peripheral Blood Mononuclear Cell GenoSure Archive data

For 8 participants, no archived resistance data were available

## Patient Reported Outcomes

<div style=\"page-break-after: always\"></div>

The palatability of the 2.5-mg RPV tablets dispersed in water was assessed in a palatability questionnaire after 2 weeks of treatment by documenting the participant's perception using a 5-point hedonic scale. Responses were available from 8 participants: 1 received the 12.5-mg dose and 7 received the 15-mg dose. The 8 respondents rated the taste of the 2.5-mg tablets dispersed in water as \"okay\" (12.5%), \"pretty good\" (12.5%) or \"really good\" (75%).

Swallowability was assessed in participants who received the 25-mg tablet formulation to be taken whole. Fifteen participants who took the 25-mg tablet (including 1 participant who switched from 15 mg to 25 mg due to weight increase) provided responses to the questionnaire. Of these, 1 (6.7%) participant who took the 25-mg tablet found it hard to swallow, whereas the other 14 (93.3%) participants found it easy to swallow. When rating the long-term daily use, 1 (6.7%) participant found it unacceptable, 3 (20.0%) found it acceptable, and 11 (73.3%) found it good to take for a longer period.

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Summary of Efficacy for trial

Table 11. Summary of efficacy for trial TMC278-TiDP38-C213 Cohort 2

| Title: A Phase II, Open-label, Single-arm Trial to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naïve HIV-1 Infected Adolescents and Children Aged ≥ 6 to <18 Years (PAINT)   | Title: A Phase II, Open-label, Single-arm Trial to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naïve HIV-1 Infected Adolescents and Children Aged ≥ 6 to <18 Years (PAINT)   | Title: A Phase II, Open-label, Single-arm Trial to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naïve HIV-1 Infected Adolescents and Children Aged ≥ 6 to <18 Years (PAINT)   | Title: A Phase II, Open-label, Single-arm Trial to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naïve HIV-1 Infected Adolescents and Children Aged ≥ 6 to <18 Years (PAINT)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                       | TMC278-TiDP38-C213 Cohort 2                                                                                                                                                                                                                            | TMC278-TiDP38-C213 Cohort 2                                                                                                                                                                                                                            | TMC278-TiDP38-C213 Cohort 2                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                 | Phase 2, open-label, single-arm, multicenter study                                                                                                                                                                                                     | Phase 2, open-label, single-arm, multicenter study                                                                                                                                                                                                     | Phase 2, open-label, single-arm, multicenter study                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                 | Duration of main phase: Duration of screening period: Duration of Extension phase:                                                                                                                                                                     | Duration of main phase: Duration of screening period: Duration of Extension phase:                                                                                                                                                                     | 48 weeks Maximum 8 weeks 4 years                                                                                                                                                                                                                       |
| Hypothesis                                                                                                                                                                                                                                             | No hypothesis                                                                                                                                                                                                                                          | No hypothesis                                                                                                                                                                                                                                          | No hypothesis                                                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                                                                                      | ARV treatment-naïve, HIV-1 infected children ≥ 6 to <12 years of age                                                                                                                                                                                   | ARV treatment-naïve, HIV-1 infected children ≥ 6 to <12 years of age                                                                                                                                                                                   | RPV once daily in combination with an investigator-selected background regimen containing 2 N(t)RTIs: AZT, ABC, or TDF in combination with 3TC or FTC (age-appropriate formulations were to be used)                                                   |
| Endpoints and definitions                                                                                                                                                                                                                              | Co-Primary endpoint                                                                                                                                                                                                                                    | Safety and tolerability                                                                                                                                                                                                                                | Safety and tolerability of RPV                                                                                                                                                                                                                         |
| Endpoints and definitions                                                                                                                                                                                                                              | Co-Primary endpoint                                                                                                                                                                                                                                    | PK                                                                                                                                                                                                                                                     | Steady-state PK parameters including Cmax, Cmin, AUC24h, Tmax, and CL/F                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                              | Secondary endpoint                                                                                                                                                                                                                                     | Efficacy                                                                                                                                                                                                                                               | Virologic response (defined as plasma viral load <50 copies/mL)                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                                                                                                                              | Secondary endpoint                                                                                                                                                                                                                                     | Efficacy                                                                                                                                                                                                                                               | Change from baseline in CD4+ cell count                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                              | Secondary endpoint                                                                                                                                                                                                                                     | Resistance determinatio n                                                                                                                                                                                                                              | Plasma-based deep sequencing, PBMC-based proviral DNA sequencing                                                                                                                                                                                       |
| Database lock                                                                                                                                                                                                                                          | 12 October 2022                                                                                                                                                                                                                                        | 12 October 2022                                                                                                                                                                                                                                        | 12 October 2022                                                                                                                                                                                                                                        |
| Results and Analysis                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                   |
| Analysis description                                                                                                                                                                                                                                   | Main Efficacy Analyses                                                                                                                                                                                                                                 | Main Efficacy Analyses                                                                                                                                                                                                                                 | Main Efficacy Analyses                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Title: A Phase II, Open-label, Single-arm Trial to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naïve HIV-1 Infected Adolescents and Children Aged ≥ 6 to <18 Years (PAINT)   | Title: A Phase II, Open-label, Single-arm Trial to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naïve HIV-1 Infected Adolescents and Children Aged ≥ 6 to <18 Years (PAINT)   | Title: A Phase II, Open-label, Single-arm Trial to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naïve HIV-1 Infected Adolescents and Children Aged ≥ 6 to <18 Years (PAINT)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                       | TMC278-TiDP38-C213 Cohort 2                                                                                                                                                                                                                            | TMC278-TiDP38-C213 Cohort 2                                                                                                                                                                                                                            |
| Analysis population and time point description                                                                                                                                                                                                         | FAS 48 weeks                                                                                                                                                                                                                                           | FAS 48 weeks                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Treatment group                                                                                                                                                                                                                                        | ARV treatment-naïve, HIV-1 infected children ≥ 6 to <12 years of age                                                                                                                                                                                   |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Number of subjects                                                                                                                                                                                                                                     | 18                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Virologic response HIV-1 RNA <50 copies/ mL, n (%)                                                                                                                                                                                                     | 13/18 (72.2%)                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | 95% CI                                                                                                                                                                                                                                                 | (46.52;90.31)                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Virologic failure                                                                                                                                                                                                                                      | 3/18 (16.7%)                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | 95% CI                                                                                                                                                                                                                                                 | (3.85;41.42)                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Discontinued due to AEs                                                                                                                                                                                                                                | 0/18 (0%)                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Discontinued due to reason other than AE                                                                                                                                                                                                               | 1/18 (5.6%)                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Change from baseline in CD4+ cell count (mean (SE))                                                                                                                                                                                                    | 215.9 (62.42) cells/μL                                                                                                                                                                                                                                 |

| and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naive HIV-1 Infected Adolescents and ChildrenAged ≥6 to<18Years(PAINT)   | and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naive HIV-1 Infected Adolescents and ChildrenAged ≥6 to<18Years(PAINT)   | and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral-naive HIV-1 Infected Adolescents and ChildrenAged ≥6 to<18Years(PAINT)                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Studyidentifier                                                                                                                           | TMC278-TiDP38-C213Cohort2                                                                                                                 | TMC278-TiDP38-C213Cohort2                                                                                                                                                             |
|                                                                                                                                           | Genotypicanalysis                                                                                                                         | Fiveofthe6participantswithpost-baseline standardgenotypicdatahadtreatment- emergentRPVRAMs(1/2VFs,3/3SVFs,and1 non-[S]vF)and4carriedtreatment-emergent NRTIRAMs(3/3SVFsand1non-[S]VF) |

Table 12. Summary of efficacy for trial TMC278HTX2002

| Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed (PICTURE)   | Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed (PICTURE)   | Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed (PICTURE)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                   | TMC278HTX2002                                                                                                                                                                                                                                                      | TMC278HTX2002                                                                                                                                                                                                                                                      |
| Design                                                                                                                                                                                                                                                             | Phase 2, open-label, single-arm, multicenter study                                                                                                                                                                                                                 | Phase 2, open-label, single-arm, multicenter study                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                    | Duration of main phase: Duration of screening period: Duration of Extension phase:                                                                                                                                                                                 | 48 weeks Maximum 8 weeks Optional roll over in study TMC278IFD3004                                                                                                                                                                                                 |
| Hypothesis                                                                                                                                                                                                                                                         | No hypothesis                                                                                                                                                                                                                                                      | No hypothesis                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed (PICTURE)   | Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed (PICTURE)   | Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed (PICTURE)   | Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed (PICTURE)                               | Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed (PICTURE)                               | Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed (PICTURE)                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                   | TMC278HTX2002                                                                                                                                                                                                                                                      | TMC278HTX2002                                                                                                                                                                                                                                                      | TMC278HTX2002                                                                                                                                                                                                                                                                                  | TMC278HTX2002                                                                                                                                                                                                                                                                                  | TMC278HTX2002                                                                                                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                                                                                                                  | HIV-1-infected children (aged 2 to <12 years) weighing ≥ 10 kg who are virologically suppressed                                                                                                                                                                    | HIV-1-infected children (aged 2 to <12 years) weighing ≥ 10 kg who are virologically suppressed                                                                                                                                                                    | RPV once daily in combination with an investigator-selected background regimen                                                                                                                                                                                                                 | RPV once daily in combination with an investigator-selected background regimen                                                                                                                                                                                                                 | RPV once daily in combination with an investigator-selected background regimen                                                                                                                                                                                                                 |
| Endpoints and definitions                                                                                                                                                                                                                                          | Co- Primary endpoint                                                                                                                                                                                                                                               | PK                                                                                                                                                                                                                                                                 | Area under the plasma concentration-time curve from time of administration up to 24 hours postdose of RPV                                                                                                                                                                                      | Area under the plasma concentration-time curve from time of administration up to 24 hours postdose of RPV                                                                                                                                                                                      | Area under the plasma concentration-time curve from time of administration up to 24 hours postdose of RPV                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                          | Co- Primary endpoint                                                                                                                                                                                                                                               | Safety and tolerability                                                                                                                                                                                                                                            | Incidence of grade 3/4 AEs, SAEs, HIVrelated events (including AIDS-defining illnesses and Stage-3-defining Opportunistic Illnesses in HIV Infection), and AEs leading to discontinuation of study intervention through 24 weeks of study treatment. Proportion of participants with HIV-1 RNA | Incidence of grade 3/4 AEs, SAEs, HIVrelated events (including AIDS-defining illnesses and Stage-3-defining Opportunistic Illnesses in HIV Infection), and AEs leading to discontinuation of study intervention through 24 weeks of study treatment. Proportion of participants with HIV-1 RNA | Incidence of grade 3/4 AEs, SAEs, HIVrelated events (including AIDS-defining illnesses and Stage-3-defining Opportunistic Illnesses in HIV Infection), and AEs leading to discontinuation of study intervention through 24 weeks of study treatment. Proportion of participants with HIV-1 RNA |
| Endpoints and definitions                                                                                                                                                                                                                                          | Secondary endpoint                                                                                                                                                                                                                                                 | Efficacy                                                                                                                                                                                                                                                           | <50 and ≥ 50 copies/mL using the FDA Snapshot approach through 24 and 48 weeks                                                                                                                                                                                                                 | <50 and ≥ 50 copies/mL using the FDA Snapshot approach through 24 and 48 weeks                                                                                                                                                                                                                 | <50 and ≥ 50 copies/mL using the FDA Snapshot approach through 24 and 48 weeks                                                                                                                                                                                                                 |
| Endpoints and definitions                                                                                                                                                                                                                                          | Secondary endpoint                                                                                                                                                                                                                                                 | Efficacy                                                                                                                                                                                                                                                           | Proportion of participants with HIV-1 RNA < 400 and ≥ 400 copies/mL using the FDA Snapshot approach through 24 and 48 weeks of study treatment.                                                                                                                                                | Proportion of participants with HIV-1 RNA < 400 and ≥ 400 copies/mL using the FDA Snapshot approach through 24 and 48 weeks of study treatment.                                                                                                                                                | Proportion of participants with HIV-1 RNA < 400 and ≥ 400 copies/mL using the FDA Snapshot approach through 24 and 48 weeks of study treatment.                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                          | Secondary endpoint                                                                                                                                                                                                                                                 | Efficacy                                                                                                                                                                                                                                                           | Change from baseline in CD4+ cell count                                                                                                                                                                                                                                                        | Change from baseline in CD4+ cell count                                                                                                                                                                                                                                                        | Change from baseline in CD4+ cell count                                                                                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                                                                                                                                          | Secondary endpoint                                                                                                                                                                                                                                                 | Resistance determinatio n                                                                                                                                                                                                                                          | Viral genotype at the time of virologic failure through 24 and 48 weeks of study treatment.                                                                                                                                                                                                    | Viral genotype at the time of virologic failure through 24 and 48 weeks of study treatment.                                                                                                                                                                                                    | Viral genotype at the time of virologic failure through 24 and 48 weeks of study treatment.                                                                                                                                                                                                    |
| Database lock                                                                                                                                                                                                                                                      | 12 April 2023                                                                                                                                                                                                                                                      | 12 April 2023                                                                                                                                                                                                                                                      | 12 April 2023                                                                                                                                                                                                                                                                                  | 12 April 2023                                                                                                                                                                                                                                                                                  | 12 April 2023                                                                                                                                                                                                                                                                                  |
| Results and Analysis                                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                           |
| Analysis description                                                                                                                                                                                                                                               | Main efficacy analyses                                                                                                                                                                                                                                             | Main efficacy analyses                                                                                                                                                                                                                                             | Main efficacy analyses                                                                                                                                                                                                                                                                         | Main efficacy analyses                                                                                                                                                                                                                                                                         | Main efficacy analyses                                                                                                                                                                                                                                                                         |
| Analysis population and time point description                                                                                                                                                                                                                     | FAS 24 weeks                                                                                                                                                                                                                                                       | FAS 24 weeks                                                                                                                                                                                                                                                       | FAS 24 weeks                                                                                                                                                                                                                                                                                   | FAS 24 weeks                                                                                                                                                                                                                                                                                   | FAS 24 weeks                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                    | Treatment group 2- <6 years                                                                                                                                                                                                                                        | Treatment group 2- <6 years                                                                                                                                                                                                                                        | Treatment group 2- <6 years                                                                                                                                                                                                                                                                    | 6- <12 years                                                                                                                                                                                                                                                                                   | All participants                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                    | Number of 1                                                                                                                                                                                                                                                        | Number of 1                                                                                                                                                                                                                                                        | Number of 1                                                                                                                                                                                                                                                                                    | 25                                                                                                                                                                                                                                                                                             | 26                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                    | subjects Virologic response ( <50 copies/ml) Week 24, n(%) 1 (100%)                                                                                                                                                                                                | subjects Virologic response ( <50 copies/ml) Week 24, n(%) 1 (100%)                                                                                                                                                                                                | subjects Virologic response ( <50 copies/ml) Week 24, n(%) 1 (100%)                                                                                                                                                                                                                            | 25 (100%)                                                                                                                                                                                                                                                                                      | 26 (100%)                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                    | (95% CI) (2.5;100)                                                                                                                                                                                                                                                 | (95% CI) (2.5;100)                                                                                                                                                                                                                                                 | (95% CI) (2.5;100)                                                                                                                                                                                                                                                                             | (86.28;100)                                                                                                                                                                                                                                                                                    | (86.77;100)                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                    | Change from baseline in CD4+ cell count (mean (SE)) 37.3 (32.76) cells/mm 3                                                                                                                                                                                        | Change from baseline in CD4+ cell count (mean (SE)) 37.3 (32.76) cells/mm 3                                                                                                                                                                                        | Change from baseline in CD4+ cell count (mean (SE)) 37.3 (32.76) cells/mm 3                                                                                                                                                                                                                    | Change from baseline in CD4+ cell count (mean (SE)) 37.3 (32.76) cells/mm 3                                                                                                                                                                                                                    | Change from baseline in CD4+ cell count (mean (SE)) 37.3 (32.76) cells/mm 3                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                    | Genotypic analysis As no participants met the definition of (S)VF, no standard genotypic resistance data were generated                                                                                                                                            | Genotypic analysis As no participants met the definition of (S)VF, no standard genotypic resistance data were generated                                                                                                                                            | Genotypic analysis As no participants met the definition of (S)VF, no standard genotypic resistance data were generated                                                                                                                                                                        | Genotypic analysis As no participants met the definition of (S)VF, no standard genotypic resistance data were generated                                                                                                                                                                        | Genotypic analysis As no participants met the definition of (S)VF, no standard genotypic resistance data were generated                                                                                                                                                                        |

## 2.6.5.3. In vitro biomarker test for patient selection for efficacy

## N/A

<div style=\"page-break-after: always\"></div>

## 2.6.5.4. Analysis performed across trials (pooled analyses and meta-analysis)

Due to the differences in study populations and in duration of follow-up in C213 Cohort 2 versus HTX2002, no formal cross-study comparison nor pooling of antiviral activity/efficacy data was performed.

When comparing ARV treatment-naïve HIV-1 infected participants, results for C213 Cohort 2 (children) were generally in line with those observed for adolescents and adults.

## 2.6.5.5. Supportive study(ies)

N/A

## 2.6.6. Discussion on clinical efficacy

The aim of the application is to extend the current approved EDURANT indication to allow the use of RPV in HIV-1 infected ARV treatment-naïve patients (HIV1 RNA ≤100,000 copies/mL) aged ≥2 years and weighing ≥10 kg and in virologically suppressed children (HIV1 RNA &lt;50 copies/mL) aged ≥2 to &lt;12 years and weighing ≥10 kg. The clinical data submitted to support the proposed extension of the indication consists of:

- The Week 48 final analysis of the PK, safety/tolerability, and efficacy data of RPV in ARV treatmentnaïve HIV1 infected children aged ≥6 to &lt;12 years (Cohort 2) with a body weight of ≥17 kg from Study C213.

- The Week 24 primary analysis and the Week 48 final analysis of the PK, safety/tolerability, and efficacy data of RPV in virologically suppressed HIV1 infected children aged ≥2 to &lt;12 years with a body weight of ≥10 kg from Study TMC278HTX2002 (referred to as HTX2002).

## Design and conduct of clinical studies

Both studies are not powered for a precise estimate of efficacy and no control arm is available for comparison. Rather, given that exposure is comparable, efficacy will be estimated through a PK/PDbridge which is in line with EMA guidance.

## Efficacy data and additional analyses

Study C213 Cohort 2 has been assessed in procedure EMEA/H/C/002264/P46. The overall conclusion from that procedure was that ' Although this is a single-arm open-label trial, based on the provided safety data, RPV seems generally safe and well tolerated when administered in combination with an investigator-selected background regimen of 2 NRTIs in HIV-1 infected treatment-naïve children ≥ 6 to &lt;12 years of age, especially in relation to available safety data in older age groups. In addition, virologic response rates &lt;50 copies/mL and &lt;400 copies/mL were respectively 72.2% and 83.3% .'

The second study, study HTX2002, was a study in virologically suppressed treatment experienced children aged 2 to 12 years of age, with a body weight of at least 10 kg. All participants remained virologically suppressed (plasma HIV1 RNA VL &lt;50 copies/mL) up to week 48, and none had virologic failure. The actual enrolled population was however comprised of children 6 years of age and older, with a body weight of 16 kg and higher. There is therefore no clinical data to support the use of RPV in the youngest age category of 2 to 6 years and/or in children with a body weight below 16 kg. The MAH

<div style=\"page-break-after: always\"></div>

wa s requested to justify the use of the RPV dispersible tablets in the youngest age category (2 to &lt;6 years) and justify the proposed lower weight cut-off. This was raised as a Multidisciplinary MO. The MAH acknowledges the limitations of the included studies to support the extension of indication to patients aged ≥ 2 to &lt;12 years and weighing ≥ 10 kg, and proposes to increase the lower weight limit from 'at least 10 kg' to 'at least 14 kg', and to delete the lower age boundary from the indication. Based on the final PopPK model, the simulated mean AUC in paediatric patients with a body weight of 14 to 16 kg is marginally above 150% of the AUC in adults (ie, specifically 162% at 14 kg), but the upper limit of the 90% prediction interval of Cmax (i.e., 460 ng/mL at 14 kg) is below the safety threshold of 750 ng/mL, calculated based on a 80% chance to observe a negative TQT trial. However, the MAH should justify the proposed weight cut-off in relation to the safety threshold for Cmax that was derived as requested in remaining OC of question 46. Furthermore, if an acceptable dose can be identified in lighter patients (down to 10 kg), this was requested to be pursued. If the previously proposed dose of 12.5 mg QD results in overexposure in patients &lt;14kg, the MAH was also requested to discuss the possibility of a lower dosing regimen in patients weighing 10-14 kg. To address this question, the MAH simulated alternative, lower dosing regimen to explore whether an acceptable RPV exposure, in terms of both Cmax and AUC, in paediatric patients weighing ≥ 14 kg to &lt; 20 kg could be achieved. Furthermore, as no paediatric patients below 16.2 kg were included in study HTX2002, RPV exposures in this weight group were simulated based on additional modelling and simulation. The simulated 95 th  % PI of Cmax for paediatric patients of 10 years old was 611 ng/mL, and thus exceeds the safety threshold, which supports to increase the lower weight limit of 'at least 10 kg'. Moreover, increasing the lower weight limit to ≥ 14 kg would align with the corresponding WHO weight band for ARVs (ie, 14 to &lt;20 kg) and better reflects the paediatric population included in study HTX2002. In this light, increasing the lower weight limit to ≥ 14 kg is acceptable to the CHMP. the 25-mg film-coated tablet were assessed using questionnaires in studies HTX2002 and C213 Cohort

Besides, the palatability of the 2.5-mg RPV tablets dispersed in water as well as the swallowability of 2, respectively. The 8 participants in study HTX2002 who received the dispersible tablets rated the taste of the 2.5-mg tablets dispersed in water as \"okay\" (12.5%), \"pretty good\" (12.5%) or \"really good\" (75%). Of the fifteen participants who took the 25-mg tablet in study C213 Cohort 2 (including 1 participant who switched from 15 mg to 25 mg due to weight increase), 1 (6.7%) participant who took the 25-mg tablet found it hard to swallow, whereas the other 14 (93.3%) participants found it easy to swallow. When rating the long-term daily use, 1 (6.7%) participant found it unacceptable, 3 (20.0%) found it acceptable, and 11 (73.3%) found it good to take for a longer period. Swallowability of the 25 mg tablet is overall acceptable.

Children are a challenging population to treat, due to e.g. adherence issues. RPV has a low barrier to resistance and development of RAMs is seen quite frequently. In the submitted studies, treatmentemergent RPV RAMs were reported in 5 participants (all in study C213 Cohort 2). One of these participants was reported with virologic failure (ie, lack or loss of virologic response), 3 participants met suspected virologic failure criteria only, and 1 participant did not meet (suspected) virologic failure criteria. This is generally in line with what has been observed in adults and adolescents, and is reflected already in section 4.4 of the SmPC.

Although Edurant 25 mg film-coated tablets is indicated for the treatment of HIV-1 infection in antiretroviral treatment naïve patients with a viral load ≤ 100,000 HIV 1 RNA copies/ml, study HTX2002 enrolled a population of children 2 to 10 years of age who have been on a stable ARV regimen for at least 6 months. Based on these results, the MAH is claiming an additional indication for Edurant, namely treatment of virologically suppressed (HIV-1 RNA less than 50 copies per mL) paediatric patients less than 12 years of age. This was agreed - after adding that patients should not have known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor. However, the MAH was requested to not limit this to paediatric patients less than 12 years of age, but reword the

<div style=\"page-break-after: always\"></div>

therapeutic indication to a combined indication including both treatment naïve as well as treatment experienced paediatric, adolescent and adult patients rather than 2 separate indications. Also considering that RPV has been approved for use in adults who are virologically-suppressed (HIV-1 RNA &lt;50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor, as part of the fixed-dose combination product Juluca (RPV+DTG). Also the fixed dose combinations Odefsey and Eviplera (RPV+FTC+TAF/TDF) can be used in treatment experienced adults and adolescents aged 12 years of age and older.

## 2.6.7. Conclusions on the clinical efficacy

Given that exposure is comparable, rilpivirine can be considered effective in the treatment of HIV-1 in paediatric patients with an HIV1 viral load &lt;100.000 copies/mL .

## 2.6.8. Clinical safety

## 2.6.8.1. Patient exposure

Across Study C213 Cohort 2 and Study HTX2002, 78 participants were screened, and 44 participants were enrolled. (Table 13)

All participants enrolled also received at least 1 dose of RPV and were therefore included in the FAS.

The overall mean (SD) and median (range) treatment duration in Study C213 Cohort 2 was 100.2 (63.26) and 69.5 (35 to 218) weeks, respectively. The total RPV exposure up to end of study was 34.57 patient years. At the time of the final analysis of Study HTX2002, the mean (SD) treatment duration was 48.6 (1.01) weeks, and median (range) treatment duration was 48.4 (47 to 52) weeks. The total RPV exposure was 24.2 patient years. (Table 13)

<div style=\"page-break-after: always\"></div>

Table 13. Enrollment Numbers by Age and Weight Group at Baseline Across Studies TMC278-TiDP38C213 Cohort 2 and TMC278HTX2002

|                                         | TMC278-TiDP38- C213 Cohort 2   | TMC278HTX2002   | Combined   |
|-----------------------------------------|--------------------------------|-----------------|------------|
| Total Number of Participants Screened   | 38                             | 40              | 78         |
| Total Number of Participants Enrolled   | 18                             | 26              | 44         |
| Age (categorical), n (%) N              | 18                             | 26              | 44         |
| 2- <6 years                             | -                              | 1 (3.8%)        | 1 (2.3%)   |
| 6- <9 years                             | 8 (44.4%)                      | 8 (30.8%)       | 16 (36.4%) |
| 9- <12 years                            | 10 (55.6%)                     | 17 (65.4%)      | 27 (61.4%) |
| Weight (categorical) at baseline, n (%) |                                |                 |            |
| N                                       | 18                             | 26              | 44         |
| < 20 kg                                 | 2 (11.1%)                      | 3 (11.5%)       | 5 (11.4%)  |
| 20 - < 25 kg                            | 7 (38.9%)                      | 5 (19.2%)       | 12 (27.3%) |
| >= 25 kg                                | 9 (50.0%)                      | 18 (69.2%)      | 27 (61.4%) |
| Treatment duration (weeks)              |                                |                 |            |
| Mean (SD)                               | 100.2 (63.26)                  | 48.6 (1.01)     |            |
| Median (range)                          | 69.5 (35 to 218)               | 48.4 (47 to 52) |            |

Note: N = number of participants with data, n = number of participants with that observation

Sources: [TSIDS01A.RTF] [TMC278\\HTX2002\\DBR\\_PA\\_WK24\\RE\\_PA\\_WK24\\PROD\\ TSIDS01A.SAS] 09DEC2022, 07:23 [TSIDS01.RTF] [TMC278\\TIDP38C213\\DBR\\_CH2\\_FA\\_WK48\\RE\\_CH2\\_FA\\_WK48\\PROD\\ TSIDS01.SAS] 02DEC2022, 16:47

## 2.6.8.2. Adverse events

## 2.6.8.3. Patient exposure

Across Study C213 Cohort 2 and Study HTX2002, 78 participants were screened, and 44 participants were enrolled.

All participants enrolled also received at least 1 dose of RPV and were therefore included in the FAS.

The overall mean (SD) and median (range) treatment duration in Study C213 Cohort 2 was 100.2 (63.26) and 69.5 (35 to 218) weeks, respectively. The total RPV exposure up to end of study was 34.57 patient years. At the time of the final analysis of Study HTX2002, the mean (SD) treatment duration was 48.6 (1.01) weeks, and median (range) treatment duration was 48.4 (47 to 52) weeks. The total RPV exposure was 24.2 patient years.

<div style=\"page-break-after: always\"></div>

Table 14. Enrollment Numbers by Age and Weight Group at Baseline Across Studies TMC278-TiDP38C213 Cohort 2 and TMC278HTX2002

|                                         | TMC278-TiDP38- C213 Cohort 2   | TMC278HTX2002   | Combined   |
|-----------------------------------------|--------------------------------|-----------------|------------|
| Total Number of Participants Screened   | 38                             | 40              | 78         |
| Total Number of Participants Enrolled   | 18                             | 26              | 44         |
| Age (categorical), n (%) N              | 18                             | 26              | 44         |
| 2- <6 years                             | -                              | 1 (3.8%)        | 1 (2.3%)   |
| 6- <9 years                             | 8 (44.4%)                      | 8 (30.8%)       | 16 (36.4%) |
| 9- <12 years                            | 10 (55.6%)                     | 17 (65.4%)      | 27 (61.4%) |
| Weight (categorical) at baseline, n (%) |                                |                 |            |
| N                                       | 18                             | 26              | 44         |
| < 20 kg                                 | 2 (11.1%)                      | 3 (11.5%)       | 5 (11.4%)  |
| 20 - < 25 kg                            | 7 (38.9%)                      | 5 (19.2%)       | 12 (27.3%) |
| >= 25 kg                                | 9 (50.0%)                      | 18 (69.2%)      | 27 (61.4%) |
| Treatment duration (weeks)              |                                |                 |            |
| Mean (SD)                               | 100.2 (63.26)                  | 48.6 (1.01)     |            |
| Median (range)                          | 69.5 (35 to 218)               | 48.4 (47 to 52) |            |

Note: N = number of participants with data, n = number of participants with that observation Sources: [TSIDS01A.RTF] [TMC278\\HTX2002\\DBR\\_PA\\_WK24\\RE\\_PA\\_WK24\\PROD\\ TSIDS01A.SAS] 09DEC2022, 07:23 [TSIDS01.RTF] [TMC278\\TIDP38C213\\DBR\\_CH2\\_FA\\_WK48\\RE\\_CH2\\_FA\\_WK48\\PROD\\ TSIDS01.SAS]

02DEC2022, 16:47

## C213 Cohort 2

A summary of AEs by dose-weight group and by study phase is presented in Table 15.

<div style=\"page-break-after: always\"></div>

Table 15. Overall Summary of Treatment Emergent Adverse Event by Dose-Weight Group; Full Analysis Set (Study TMC278-TiDP38-C213 Cohort 2)

|                                                                                   | rilpivirine       | rilpivirine         | rilpivirine       | rilpivirine      | rilpivirine              | rilpivirine      |
|-----------------------------------------------------------------------------------|-------------------|---------------------|-------------------|------------------|--------------------------|------------------|
|                                                                                   | 12.5 mg qd, <20kg | 15 mg qd, 20- <25kg | 25 mg qd, <25kg   | 25 mg qd, >=25kg | All RPV Recommended Dose | All Participants |
| Analysis set: Full Analysis Set                                                   | 2                 | 2                   | 5                 | 9                | 13                       | 18               |
| 48-week treatment period: Participants,                                           | 2                 | 2                   | 5                 | 9                | 13                       | 18               |
| n (%) with at least one AE                                                        | 2 (100%)          | 2 (100%)            | 5 (100%)          | 8 (88.9%)        | 12 (92.3%)               | 17 (94.4%)       |
| with a DAIDS grade 1 AE or mild AE                                                | 2 (100%)          | 2 (100%)            | 5 (100%)          | 6 (66.7%)        | 10 (76.9%)               | 15 (83.3%)       |
| with a DAIDS grade 2 AE or moderate AE                                            | 0                 | 0                   | 2 (40.0%)         | 6 (66.7%)        | 6 (46.2%)                | 8 (44.4%)        |
| with an AE which is related a to RPV                                              | 0                 | 0                   | 0                 | 1 (11.1%)        | 1 (7.7%)                 | 1 (5.6%)         |
| with an AE which is possibly related to background regimen                        | 0                 | 0                   | 0                 | 1 (11.1%)        | 1 (7.7%)                 | 1 (5.6%)         |
| with an AE which is related a to background regimen                               | 0                 | 0                   | 0                 | 1 (11.1%)        | 1 (7.7%)                 | 1 (5.6%)         |
| Post-Week 48 extension period: Participants, n (%)                                | 0                 | 1                   | 5                 | 6                | 7                        | 12               |
| with at least one AE                                                              | 0                 | 1 (100%)            | 2                 | 4 (66.7%)        | 5 (71.4%)                | 7 (58.3%)        |
| with a DAIDS grade 1 AE or mild AE                                                | 0                 | 1 (100%)            | (40.0%) 2 (40.0%) | 2 (33.3%)        | 3 (42.9%)                | 5 (41.7%)        |
| with a DAIDS grade 2 AE or moderate AE                                            | 0                 | 0                   | 1 (20.0%)         | 3 (50.0%)        | 3 (42.9%)                | 4 (33.3%)        |
| with a DAIDS grade 2, 3 or 4 AE                                                   | 0                 | 0                   | 1 (20.0%)         | 3 (50.0%)        | 3 (42.9%)                | 4 (33.3%)        |
| Treatment phase: Participants, n (%)                                              | 2                 | 2                   | 5                 | 9                | 13                       | 18               |
| with at least one AE                                                              | 2 (100%)          | 2 (100%)            | 5 (100%)          | 8 (88.9%)        | 12 (92.3%)               | 17 (94.4%)       |
| with a DAIDS grade 1 AE or mild AE                                                | 2 (100%)          | 2 (100%)            | 5 (100%)          | 7 (77.8%)        | 11 (84.6%)               | 16 (88.9%)       |
| with a DAIDS grade 2 AE or moderate AE                                            | 0                 | 0                   | 2 (40.0%)         | 6 (66.7%)        | 6 (46.2%)                | 8 (44.4%)        |
| with a DAIDS grade 2, 3 or 4 AE                                                   | 0                 | 0                   | 2 (40.0%)         | 6 (66.7%)        | 6 (46.2%)                | 8 (44.4%)        |
| with an AE which is possibly related to RPV                                       | 0                 | 0                   | 0                 | 1 (11.1%)        | 1 (7.7%)                 | 1 (5.6%)         |
| with an AE which is related a to RPV                                              | 0                 | 0                   | 0                 | 1 (11.1%)        | 1 (7.7%)                 | 1 (5.6%)         |
| with an AE which is possibly                                                      | 0                 | 0                   | 0                 | 1 (11.1%)        | 1 (7.7%)                 | 1 (5.6%)         |
| related to background regimen with an AE which is related a to background regimen | 0                 | 0                   | 0                 | 1 (11.1%)        | 1 (7.7%)                 | 1 (5.6%)         |

<div style=\"page-break-after: always\"></div>

Key: AE= adverse event; DAIDS = Division of AIDS; RPV = rilpivirine; SAE= serious adverse event a  An AE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study treatment OR background regimen

Note: n = number of participants with that particular AE; % = percentage of participants with that particular AE against the total number of participants

Note: Denominator for post-Week 48 extension period is the number of participants who enrolled in this treatment period

Rilpivirine dose group is determined by the initial administered dose, irrespective of subsequent dosealterations.

RPV Recommended dose: 12.5mg qd for &lt;20kg, 15mg qd for 20 -&lt;25kg, 25mg qd for &gt;=25kg

Adapted from: [TSFAE01A.RTF] [TMC278\\TIDP38C213\\DBR\\_CH2\\_FA\\_WK48\\RE\\_CH2\\_FA\\_WK48\\PROD\\TSFAE01A.SAS] 02DEC2022, 16:38

In the 48-week treatment period, 17/18 (94.4%) participants were reported with AEs. The most commonly reported AEs (in ≥ 2 participants overall) were upper respiratory tract infection (12/18 [66.7%] participants), and otitis media, decreased appetite, anaemia, diarrhoea, vomiting, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, cough, and rash (2/18 [11.1%] participants). In the post-Week 48 extension period, 7/12 (58.3%) participants were reported with AEs. Upper respiratory tract infection was the only AE reported in more than 1 participant (5/12 [41.7%] participants).

AEs that were considered by the investigator as possibly related to RPV included non-serious Grade 1 ALT increased and Grade 1 AST increased, both reported in the same participant, in the 25 mg qd ( ≥ 25 kg) dose-weight group in the 48-week treatment period. No action was taken as a result of the events, which resolved spontaneously during the 48-week treatment period. The participant continued receiving RPV and rolled over to Study TMC278IFD3004. No other AEs were considered by the investigator to be at least possibly related to RPV during the study. One AE of upper respiratory tract infection was documented as HIVrelated event in the eCRF in a participant in the 25 mg qd, &lt;25 kg dose-weight group in the 48-week treatment period. No other AEs were considered to be HIV-related during the study.

## HTX2002

A high-level summary of AEs by dose-weight group for the 48-week primary analysis is presented in Table 16.

Overall, 19 (73.1%) participants had at least one AE. Three of 26 (11.5%) participants had an AE considered to be at least possibly related to RPV by the investigator (2 in the 25 mg qd [ ≥ 25 kg] dose weightgroup and 1 in the 12.5 mg qd [&lt;20 kg] dose -weight group), and 2/26 (7.7%) participants had AEs considered at least possibly related to background regimen by the investigator (1 in the 25 mg qd [ ≥ 25 kg] dose weightgroup and 1 in the 12.5 mg qd [&lt;20 kg] dose -weight group). All AEs were DAIDS Grade 1 or 2 in severity.

<div style=\"page-break-after: always\"></div>

Table 16. Overall Summary of Treatment Emergent Adverse Events by Age Group; Full Analysis Set (Study TMC278HTX2002)

|                                                                                | ≥2 - < 6 years   | rilpivirine ≥6 - < 12 years   | All Participants   |
|--------------------------------------------------------------------------------|------------------|-------------------------------|--------------------|
| Analysis set: Full Analysis Set                                                | 1                | 25                            | 26                 |
| Participants, n (%)                                                            |                  |                               |                    |
| with at least one AE                                                           | 1 (100%)         | 18 (72.0%)                    | 19 (73.1%)         |
| with at least one SAE                                                          | 0                | 0                             | 0                  |
| who died due to an AE a                                                        | 0                | 0                             | 0                  |
| with a DAIDS grade 1 AE or mild AE                                             | 1 (100%)         | 16 (64.0%)                    | 17 (65.4%)         |
| with a DAIDS grade 2 AE or moderate AE                                         | 1 (100%)         | 7 (28.0%)                     | 8 (30.8%)          |
| with a DAIDS grade 3 AE or severe AE                                           | 0                | 0                             | 0                  |
| with a DAIDS grade 4 AE or potentially life-threatening AE                     | 0                | 0                             | 0                  |
| with a DAIDS grade 2, 3 or 4 AE                                                | 1 (100%)         | 7 (28.0%)                     | 8 (30.8%)          |
| with a DAIDS grade 3 or 4 AE                                                   | 0                | 0                             | 0                  |
| with a missing DAIDS grade                                                     | 0                | 0                             | 0                  |
| with at least one AE for which the trial medication was permanently stopped    | 0                | 0                             | 0                  |
| with at least one AE for which the trial                                       | 0                | 0                             | 0                  |
| medication was temporarily stopped with an AE which is possibly related to RPV | 0                | 1 (4.0%)                      | 1 (3.8%)           |
| with an AE which is probably related to RPV                                    | 0                | 0                             | 0                  |
| with an AE which is very likely related to RPV                                 | 1 (100%)         | 1 (4.0%)                      | 2 (7.7%)           |
| with an AE which is related b to RPV                                           | 1 (100%)         | 2 (8.0%)                      | 3 (11.5%)          |
| with an SAE which is related b to RPV                                          | 0                | 0                             | 0                  |
| with an AE which is possibly related to                                        | 0                | 1 (4.0%)                      | 1 (3.8%)           |
| background regimen with an AE which is probably related to                     | 0                | 0                             | 0                  |
| background regimen with an AE which is very likely related                     | 1 (100%)         | 0                             | 1 (3.8%)           |
| to background regimen with an AE which is related b to                         | 1 (100%)         | 1 (4.0%)                      | 2 (7.7%)           |
| background regimen with an SAE which is related b to                           | 0                | 0                             | 0                  |
| background regimen                                                             |                  |                               |                    |

Key: AE= adverse event; SAE= serious adverse event

a  AEs leading to death are based on AE outcome of Fatal

b  An AE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study treatment / background regimen

Note: n = number of participants with that particular AE; % = percentage of participants with that particular AE against the total number of participants

Adapted from: [TSFAE01A.RTF] [PROD/TMC278/HTX2002/DBR\\_FA\\_WK48/RE\\_FA\\_WK48/TSFAE01A.SAS] 28APR2023, 11:14

At the Week 48 analysis, the most frequently reported AEs were in the Gastrointestinal Disorders (8 [30.8%] participants) and Infections and Infestations (7 [26.9%] participants) SOCs. The most frequently reported AE by PT were vomiting in 4 (15.4%) participants and ALT increased in 3 (11.5%) participants. All other AEs by PT were reported in at most 2 participants. (Table 17)

A total of 6 AEs, all Grade 1, in 3 (11.5%) participants were reported to be at least possibly related to RPV (2 in the 25 mg qd [ ≥ 25 kg] dose weightgroup and 1 in the 12.5 mg qd [&lt;20 kg] dose -weight

<div style=\"page-break-after: always\"></div>

group). These were vomiting in 1 participant; abdominal pain in 1 participant; and nausea, vomiting, cortisol decreased, and folate deficiency in a third participant.

None of the events stated led to study drug discontinuation.

Table 17. Adverse Events: Tabulation of Treatment Emergent Events by SOC in at least 5% of the Participants; Full Analysis Set (Study TMC278HTX2002)

|                                                 | ≥2 - <6 years   | ≥6 -< 12 years   | All Participants   |
|-------------------------------------------------|-----------------|------------------|--------------------|
| Analysis set: Full Analysis Set                 | 1               | 25               | 26                 |
| Number of participants, n (%)                   |                 |                  |                    |
| Participants with 1 or more AEs                 | 1 (100.0%)      | 18 (72.0%)       | 19 (73.1%)         |
| Gastrointestinal disorders                      | 1 (100.0%)      | 7 (28.0%)        | 8 (30.8%)          |
| Vomiting                                        | 1 (100.0%)      | 3 (12.0%)        | 4 (15.4%)          |
| Abdominal pain                                  | 0               | 2 (8.0%)         | 2 (7.7%)           |
| Nausea                                          | 0               | 2 (8.0%)         | 2 (7.7%)           |
| Infections andinfestations                      | 1 (100.0%)      | 6 (24.0%)        | 7 (26.9%)          |
| Rhinitis                                        | 1 (100.0%)      | 1 (4.0%)         | 2 (7.7%)           |
| Upper respiratory tract infection               | 0               | 2 (8.0%)         | 2 (7.7%)           |
| Investigations                                  | 1 (100.0%)      | 5 (20.0%)        | 6 (23.1%)          |
| Alanine aminotransferase increased              | 0               | 3 (12.0%)        | 3 (11.5%)          |
| Aspartate aminotransferaseincreased             | 0               | 2 (8.0%)         | 2 (7.7%)           |
| Nervous system disorders                        | 0               | 5 (20.0%)        | 5 (19.2%)          |
| Headache                                        | 0               | 2 (8.0%)         | 2 (7.7%)           |
| Respiratory, thoracic and mediastinal disorders | 0               | 4 (16.0%)        | 4 (15.4%)          |
| Nasal congestion                                | 0               | 2 (8.0%)         | 2 (7.7%)           |
| General disorders and administration site       |                 |                  |                    |
| conditions                                      | 1 (100.0%)      | 2 (8.0%)         | 3 (11.5%)          |
| Pyrexia                                         | 1 (100.0%)      | 1 (4.0%)         | 2 (7.7%)           |
| Metabolismand nutritiondisorders                | 0               | 3 (12.0%)        | 3 (11.5%)          |
| Decreased appetite                              | 0               | 2 (8.0%)         | 2 (7.7%)           |

Key: AE= adverse event

Note: Participants are counted only once for any given event, regardless of the number of times they actually experienced the event

Note: Adverse events are coded using MedDRAVersion 25.1

Note: n =number ofparticipants with that paiticular AE; %=percentage ofparticipants with that particular AE against the total number of participants

## 2.6.8.4. Serious adverse event/deaths/other significant events

No SAEs or deaths were reported during Studies C213 Cohort 2 and HTX2002.

AEs of interest are identified as skin events, neuropsychiatric events, potential QT-prolongation-related events, hepatic events, endocrinology events, and Stage 3-defining opportunistic infections.

## C213 Cohort 2

AEs of interest were reported in a total of 8/18 (44.4%) participants during the study; 6/18 (33.3%) participants had AEs of special interest in the 48-week treatment period, and 2/12 (16.7%) participants had AEs of special interest during the post-Week 48 extension period.

rilpivirine

<div style=\"page-break-after: always\"></div>

All AEs of interest were DAIDS toxicity Grade 1 or 2, and all were non-serious and considered not related to the study intervention by the investigator, except for 1 participant with Grade 1 ALT/AST increased (possibly related). There were no AEs of interests which led to study discontinuation, and all events resolved while on study treatment, except for the AE of abnormal ACTH stimulation test.

AEs of interest observed in the study:

Hepatic events: Two participants (2/18 [11.1%]) had a Grade 1 ALT increased and a Grade 1 AST increased. Other liver tests, including bilirubin, were within normal limits in these participants.

Skin events: Two participants (2/18 [11.1%]) had reports of Grade 1 rash. One participant (1/18 [5.6%]) had a Grade 1 dermatitis atopic.

Potential QT-prolongation related events: One participant (1/18 [5.6%]) had a Grade 2 electrocardiogram QT prolonged (reported at Week 12, QTcB was 469 ms and QTcF was 425 ms).

Neuropsychiatric events: One participant (1/18 [5.6%]) had a Grade 1 headache.

Endocrinology events: One participant (1/18 [5.6%]) had a Grade 1 ACTH stimulation test abnormal.

In the post-Week 48 extension period, 1/12 (8.3%) participant each was reported with Grade 1 depression and Grade 2 dermatitis atopic.

## HTX2002

AEs of interest were reported in 11 (42.3%) participants. All AEs of interest were DAIDS toxicity Grade 1 or 2, and all were considered not related to the study intervention by the investigator except for the AE of cortisol decreased. There were no AEs of interests which led to study discontinuation, and all events resolved while on study treatment.

AEs of interest observed in the study:

Hepatic events: Two (2/26 [7.7%)] participants experienced a Grade 2 ALT increased and 1 (1/26 [3.8%]) participant experienced a Grade 1 ALT increased. Two (2/26 [7.7%] participants experienced a Grade 1 AST increased. One (1/26 [3.8%]) participant experienced a Grade 1 GGT increased.

Skin events: Grade 1 rash and erythema were reported in 1 (1/26 [3.8%]) participant each.

Potential QT-prolongation related events: One participant (1/26 [3.8%]) had a Grade 2 electrocardiogram QT prolonged.

Neuropsychiatric events: Grade 1 headache was reported in 2 (2/26 [7.7%]) participants. Grade 1 amnesia, dizziness, somnolence, and ADHD were reported in 1 (1/26 [3.8%]) participant each.

Endocrinology events: One participant (1/26 [3.8%]) had a Grade 1 cortisol decreased.

## 2.6.8.5. Laboratory findings

No clinically meaningful changes in clinical laboratory values were reported in Study C213 Cohort 2 and in Study HTX2002.

In both studies, lab values related to liver enzymes were Grade 1 or 2, and similar to the profile observed in adults and adolescents. Few instances were reported as Grade 1 AEs. These were nonserious, transient events that did not result in study intervention discontinuation.

## Endocrine parameters

<div style=\"page-break-after: always\"></div>

## C213 Cohort 2

Basal cortisol at baseline was normal for 4/18 participants, low for 13/18 participants, and missing for 1/18 participants.

Among the 4 participants with normal basal cortisol at baseline, 3 participants had either normal basal cortisol levels ( ≥ 248 nmol/L) or normal cortisol levels 1 hour after ACTH stimulation ( ≥ 500 nmol/L) throughout the study and/or at the last available visit (Week 24 and Week 72); 1 participant had low basal cortisol at the last available assessment (Week48) and no ACTH stimulation test was performed. For this participant the AEs of anaemia and hypokalaemia were reported with onset date 6 days after start of RPV treatment. Both events were Grade 1, considered by the investigator as not related to RPV, and had resolved by the time of the Week 2 visit. No additional AEs suggestive of adrenal insufficiency were reported for this participant.

Among the 13 participants with low basal cortisol predose on Day 1, 2 participants had low basal and ACTH stimulated cortisol values throughout the study, including ACTH stimulated cortisol at baseline before starting treatment with RPV. One of these 2 participants had an AE of ACTH stimulation test abnormal reported at baseline which was considered by the investigator as not related to RPV or the background regimen and was ongoing at end of study. For both participants, no AEs suggestive for adrenal insufficiency were reported. The remaining 11 participants had normal serum cortisol values after ACTH stimulation at baseline and/or during treatment.

## HTX2002

Overall, 15/26 participants had normal baseline cortisol levels, either basal at T0 or at T60 after ACTH stimulation testing. Nine participants had low (&lt;248 nmol/L) basal cortisol levels on Day 1 before starting RPV treatment. For 2 participants, the baseline values were missing.

At Week 48, 6 participants had normal (basal) cortisol ( ≥ 248 nmol/L) and 19/25 participants (Week 48 result was not available for 1 participant) had low basal cortisol levels:

- In 15 participants, the Week 48 serum cortisol levels returned to normal ( ≥ 248 nmol/L) after repeat serum basal cortisol testing or was normal after ACTH stimulation testing ( ≥ 500 nmol/L [ ≥ 18.1 μ g/dL]). No AEs suggestive of adrenal insufficiency were reported in any of these 15 participants.
- In 4 participants, the serum cortisol levels remained low after repeat serum basal cortisol testing or after ACTH stimulation testing. One of those participants (in the 15 mg group; ≥ 20 to &lt;25 kg dose -weight) had consistent ACTH-stimulated cortisol values between 400-500 nmol/L during the study after normal ACTH-stimulated cortisol value at baseline. No adrenal-related AEs were reported for this one participant.

One participant with normal cortisol levels at baseline (basal value) and Week 48 (repeat basal value) had a Grade 1 low basal cortisol AE reported at Week 24 considered possibly related to RPV and background regimen (serum cortisol value at Week 24 was 247.5 nmol/L); at repeat testing 3 weeks later, the value was normal again ( ≥ 248 nmol/L).

## Other endocrine parameters

The mean (SD) change from baseline to week 48 in endocrine measurements are summarised in Table 18.

<div style=\"page-break-after: always\"></div>

Table 18. Mean (SD) Changes in Endocrine Measurements From Baseline to Week 48

| Endocrine       | C213 Cohort 2       | HTX2002             |
|-----------------|---------------------|---------------------|
| Androstenedione | 0.15 (0.359) nmol/L | 0.48 (0.727) nmol/L |
| DHEAS           | 0.25 (0.229) μmol/L | 0.50 (0.713) μmol/L |
| FSH             | 1.00 (1.854) IU/L   | 1.71 (2.966) IU/L   |
| LH              | 0.27 (0.453) IU/L   | 1.68 (5.737) IU/L   |
| Testosterone    | 0.61 (2.158) nmol/L | 1.13 (2.567) nmol/L |

## 2.6.8.6. In vitro biomarker test for patient selection for safety

N/A

## 2.6.8.7. Safety in special populations

Safety analyses by sex, race, age, or region were not performed for participants in C213 Cohort 2 and HTX2002 due to the small sample sizes in each study. No differences are expected in comparison with adults and adolescents

## 2.6.8.8. Immunological events

N/A

## 2.6.8.9. Safety related to drug-drug interactions and other interactions

No additional data are available. No differences are expected with regard to the drug-drug interaction profile in children compared to adults and adolescents.

## 2.6.8.10. Discontinuation due to adverse events

There were no AEs leading to discontinuation of study intervention in Studies C213 Cohort 2 and HTX2002.

## 2.6.8.11. Post marketing experience

The international birth date for RPV is 20 May 2011, based on its first approval of the RPV oral formulation in the USA. Oral 25 mg RPV tablets are currently registered for use in adults in more than 80 countries worldwide. Several of these countries, including USA and EU, have approved the use of oral RPV also in adolescents ( ≥ 12 to &lt;18 years of age). PBRERs/PSURs are available for RPV, covering the period from 20 May 2011 to 19 May 2022, and summarizing the postmarketing safety data obtained by Global Medical Safety of Janssen Research &amp; Development. Case reports detailing safety issues in children under age 12 taking EDURANT have not been received, and no safety signal has been identified.

<div style=\"page-break-after: always\"></div>

## 2.6.9. Discussion on clinical safety

The rilpivirine paediatric study programme is not powered to generate a comprehensive safety database in children and in the data currently presented, no control arm is available for comparison. Rather, given that exposure is comparable, safety will be extrapolated through a PK/PD-bridge which is in line with EMA guidance.

The safety profile of rilpivirine is well-established in adults and adolescents, and the safety assessment of study C213 Cohort 2 and HTX2002 did not give rise to new safety concerns. However, as it is known from use in adults and adolescents that psychiatric disorders are common with RPV, and this may also apply to younger children, it is recommended to closely monitor these ARs in future PSURs. Similarly, hepatobiliary disorders (although often asymptomatic) may occur and the implications hereof for young children are currently unknown. The MAH commits to specifically monitor psychiatric disorders and hepatobiliary disorders in paediatric patients &lt;12 years of age in future PSURs

There were 2 reports of QT-prolongation, 1 in each study. For both events, the investigator considered the AE to be not related to the study medication. This can be agreed, also taking into consideration the timing of the events (Day 88 and day 163 for 1 participant and day 162 for the other participant) and the observation that for both participants the events resolved without treatment/action and that QT intervals were normal at the other timepoints throughout the study.

No evidence of adrenal insufficiency was observed based on basal serum cortisol measurements and/or on serum cortisol values after ACTH stimulation. No signs or symptoms of adrenal insufficiency were identified.

## 2.6.10. Conclusions on the clinical safety

The safety profile of rilpivirine is well-established in adults and adolescents, and given that exposure is comparable, it is not expected to be substantially different in a paediatric setting. The limited paediatric safety dataset does not raise any age-specific issues.

## 2.7. Risk Management Plan

The MAH submitted an updated RMP version 10.1 (date of final sign off 17-July-2023) with this application. The (main) proposed RMP changes were the following:

- Update of Part I with new sought indications, formulation of product and dosage recommendation(s);
- Added data of 2 clinical trials in children ages 2 to 12 years of age, all relevant sections in Part II are updated accordingly.

## 2.7.1. Safety concerns

The MAH proposed the following summary of safety concerns in the RMP:

Table SVIII.1: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns   |
|------------------------------|------------------------------|
| Important identified risks   | none                         |
| Important potential risks    | none                         |

## Summary of safety concerns

Missing information

Pregnancy

<div style=\"page-break-after: always\"></div>

There are no important identified risks or important potential risks listed for Edurant. It is agreed by the Committee that the provided information from studies C213 Cohort 2 and HTX2002 do not necessitate an update of this section. However, the Committee had a request regarding safety concerns to be monitored as part of PSUR safety specification. Transaminases increased and bilirubin increased are known ADRs in patients &gt; 12 years of age and are included in the current SmPC section 4.8. There are concerns regarding the seriousness and consequences of prolonged elevated levels of AST and ALT in paediatric patients &lt;12 year s of age, and therefore hepatotoxicity in paediatric patients &lt;12 years of age should be included as important potential risk in the PSUR summary of safety concerns and discussed by the MAH in future PSURs.

Having considered the data in the safety specification, the following issues were addressed during the procedure:

- The information regarding clinical trial exposure in the RMP does not fully match the information found in the CSR provided by the MAH. In response to this point, it was clarified by the MAH that the clinical trial exposures mentioned in the RMP only include patients treated with the recommended dose, while the CSR also includes patients treated with another dose than the recommended one.
- Section SIV.1 should be updated. Criterion 4 ' Subjects who received any previous treatment with a therapeutic HIV vaccine or ART, with the exception of subjects who received a single dose of NVP to prevent mother-to-child transmission in the TMC278-C213 trial .' is no longer applicable (as the population enrolled in HTX2002 consisted of treatment experienced children). (OC) Further, Criterion 6 ' Children &lt;12 years old ' is no longer correct. The MAH's proposed update, stating that 'Use of EDURANT in children &lt;12 years of age was not included in the approved population at the time of the initial Marketing Authorization Application. ' is not correct and should be amended. At the time of MAA, only adults were included in the therapeutic indication. In response to this issue, the MAH amended Section SIV.1 criterion 4 as requested and additionally amended criterion 6 in this section to be in line with the new sought extended indication. Section SIV.1 of the Edurant RMP v10.2 is therefore acceptable to the Committee.

## 2.7.2. Pharmacovigilance plan

No changes in the PhV plan are proposed by the MAH as part of this updated RMP.

## Summary of planned additional PhV activities from RMP

Table Part III.3.1: On-going and planned additional pharmacovigilance activities

| Study Status                                                                                                               | Summary of objectives                                                                                                      | Safety concerns addressed                                                                                                  | Milestones                                                                                                                 | Due dates                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| Antiretroviral Pregnancy Registry Ongoing                                                                                                                                                                                  | To collect information on the risk of birth defects in patients exposed to EDURANT during pregnancy                                                                                                                        | - Pregnancy                                                                                                                                                                                                                | Submission of interim reports                                                                                                                                                                                              | Interim reports will be submitted and discussed in the PBRERs/PS URs (data lock point and periodicity as described in the List of EU reference dates and frequency of submission of PSURs)                                 |

## Overall conclusions on the PhV Plan

The Committee, having considered the data submitted, is of the opinion that the proposed postauthorisation PhV development plan is sufficient to identify and characterise the risks of the product

## 2.7.3. Risk minimisation measures

No changes in risk minimisation measures are proposed by the MAH as part of this updated RMP.

<div style=\"page-break-after: always\"></div>

## Routine Risk Minimisation Measures

Table Part V.1: Description of routine risk minimisation measures by safety concern

Table Part V.1: Description of Routine Risk Minimization Measures by Safety Concern

| Safety Concern      | Routine Risk Minimization Activities                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing information | Missing information                                                                                                                                                                                                                                                                                                                                                                            |
| Pregnancy           | Routineriskcommunication: SmPC Section 4.6 PL Section 2 Routine risk minimization activities recommending specific clinical measures to address the risk: Recommendation regarding the use of EDURANT during pregnancy is provided in SmPC Section 4.6 and PL Section 2 Other routine risk minimization measures beyond the Product Information: Legal status: restricted medical prescription |

## Additional risk minimisation measures

Routine risk minimization activities as described in Part V.1 are sufficient to manage the safety concern of the medicinal product.

## Overall conclusions on risk minimisation measures

The Committee, having considered the data submitted, is of the opinion that the proposed risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication(s).

## 2.7.4. Conclusion

The CHMP considered that the risk management plan version 10.2 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The most recent UNAIDS report estimates that of the 38.4 million people globally living with HIV in 2021, 1.7million (4.4%) were children aged 0 to 14 years (UNAIDS 2021).

The application is intended to extend the current approved EDURANT indication to allow the use of RPV in HIV-1 infected ARV treatment-naïve patients (HIV-1 RNA ≤ 100,000 copies/mL) aged ≥ 2 years and weighing ≥ 10 kg and in virologically suppressed children (HIV-1 RNA &lt;50 copies/mL) aged ≥ 2 to &lt;12 years and weighing ≥ 10 kg. The application consists of both a line extension for a novel 2.5 mg dispersible tablet as well as an extension of indication for the already approved 25 mg film-coated tablet.

The following wording is proposed by the MAH:

## Edurant 25 mg film-coated tablet:

EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and paediatric patients weighing at least 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml (see sections 4.4 and 5.1).

Genotypic resistance testing should guide the use of EDURANT (see sections 4.4 and 5.1).

## Edurant 2.5 mg dispersible tablet:

EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients 2 to less than 18 years of age and weighing at least 14 kg to less than 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml (see sections 4.4 and 5.1).

Genotypic resistance testing should guide the use of EDURANT (see sections 4.4 and 5.1).

## 3.1.2. Available therapies and unmet medical need

As for adults, HIV infection is a life-threatening condition in the paediatric population. Lifelong treatment is needed, and although treatment options have markedly improved the last decades, there remains a need to expand the available treatment options for children by additional age-appropriate formulations.

The recommended (collaborative Penta/EACS HIV treatment guideline, 2023) initial treatment of HIV-1 infection for paediatric patients is therapy with two NRTIs in combination with a drug from a different class (third agent). DTG is the preferred third agent in all children over 4 weeks of age and 3 kg. Whilst 'preferred options' are recommended, 'alternative options' are acceptable and remain important choices in settings where ART availability is limited or in individuals at particular risk of specific toxicity or DDIs.

<div style=\"page-break-after: always\"></div>

The choice of HIV-1 therapy depends on various factors including the availability of age-appropriate formulation, ease of use, age/developmental stage of the patient, prior exposure (maternal  or prevention), adherence, and in adolescent girls, the risk of pregnancy.

The goal of combination ART in paediatric patients is to achieve and sustain HIV-1 virologic suppression, preserve/restore immune function, minimize drug toxicity, prevent drug resistance, and ultimately lead to normal growth and neurocognitive development.

People living with HIV-1 who are aware of their status, take ART as prescribed, and get and keep an undetectable viral load can live healthy lives.

## 3.1.3. Main clinical studies

The clinical data submitted to support the proposed line extension and extension of the indication consists of:

- The Week 48 final analysis of the PK, safety/tolerability, and efficacy data of RPV in ARV treatmentnaïve HIV1 infected children aged ≥6 to &lt;12 years (Cohort 2) with a body weight of ≥17 kg from Study TMC278-TiDP38-C213 (n=18).
- The Week 24 primary analysis and the Week 48 final analysis of the PK, safety/tolerability, and efficacy data of RPV in virologically suppressed HIV1 infected children aged ≥2 to &lt;12 years with a body weight of ≥10 kg from Study TMC278HTX2002 (n=26).

Both studies are Phase 2, open-label, single arm, multicentre studies.

## 3.2. Favourable effects

The efficacy of Edurant has been established in adult and adolescent patients 12 years of age and older. The efficacy demonstration in children is based on a PK bridge, inferred through similar exposure as in adults (cf. EMA Guideline on the clinical development of medicinal products for the treatment of HIV infection, EMEA/CPMP/EWP/633/02 Rev. 3).

The estimated PK parameters derived from the population PK analysis, which were generally in line with the NCA results, show that plasma exposures are increased in paediatric patients in all weight categories (i.e. ≥ 1 0 to &lt;20 kg, ≥ 2 0  to &lt; 25 kg, and ≥ 25 kg) compared to adult patients (Table 19).

Table 19. Pharmacokinetic results for rilpivirine at steady state after administration of the recommended dosing regimen in paediatric patients versus adults.

RPV Dosea

WeightBand

|                               | PediatricPatients≥2to<18years C213,HTX2002   | PediatricPatients≥2to<18years C213,HTX2002   | PediatricPatients≥2to<18years C213,HTX2002   | Reference,Adults C209,C215   |
|-------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------|
| PharmacokineticsofRPv Mean±SD | 12.5 mg qd ≥10 to <20 kg                     | 15 mg qd ≥20 to <25 kg                       | 25 mg qd ≥25 kg                              | 25 mg qd                     |
| N                             | 4                                            | 7                                            | 62b                                          | 679c                         |
| AUC24h (ng.h/mL)              | 3,528±1,431d                                 | 3,197±1,051d                                 | 3,004±1,231d                                 | 2,397±1,032e                 |
| Con (ng/mL)                   | 117±47.0d                                    | 100±41.1d                                    | 100±41.0d                                    | 80.1±36.5e                   |
| Cmax (ng/mL)                  | 207±108f                                     | 201±46.5f                                    | 134±76.18                                    | 134±72.0h                    |

bN=31 for Cmax.

a The 12.5-mg and 15-mg doses were administered as 5 and 6 dispersed 2.5-mg tablets (G009-01), respectively. The 25-mg dose was administered as one 25-mg tablet (marketed formulation).

c N=44 for Cmax.

e From popPK analysis in Phase 3 Studies C209 and C215 (Week 48 analysis).

d From popPK analysis in Phase 2 Studies C213 (Cohort 1 and 2, Week 48 analysis) and HTX2002 (Week 48 analysis).

f From intensive PK analysis in Phase 2 Studies C213 (Cohort 2, Week 48 analysis) and HTX2002 (Week 48 analysis); posthoc analysis (Appendix 2.7.2.6).

hFrom intensivePK analysis inPhase3Studies C209 and C215 (Week 48 analysis).

From intensive PK analysis in Phase 2 Studies C213 (Cohort 1 and 2, Week 48 analysis) and HTX2002 (Week 48 analysis); posthoc analysis (Appendix 2.7.2.6).

In study C213 Cohort 2, an overall 72% of patients (13/18 ) reached viral load &lt;50 copies/mL at week 48. In study HTX2002 all participants remained virologically suppressed (plasma HIV-1 RNA VL &lt;50 copies/mL) up to week 48.

<div style=\"page-break-after: always\"></div>

The palatability of the 2.5-mg RPV tablets dispersed in water as well as the swallowability of the 25-mg film-coated tablet were considered adequate.

## 3.3. Uncertainties and limitations about favourable effects

## Cut-off therapeutic indication

There is no PK, efficacy, or safety data to support the use of RPV in the youngest age category of 2 to 6 years and/or in children with a body weight below 16 kg. The exposure in this age/body weight group was only simulated using the final popPK model and simulated to be exceeding the 150% of the target exposure boundary of the predicted adult exposure. The MAH acknowledges the limitations of the included studies to support the extension of indication to patients aged ≥ 2 to &lt;12 years and weighing ≥ 10 kg and proposes to increase the lower weight limit from ' at least 10 kg ' to ' at least 14 kg ' , and to delete the lower age boundary from the indication. Based on the final PopPK model, the predicted mean AUC in paediatric patients with a body weight of 14 to 16 kg is marginally above 150% of the AUC in adults (ie, specifically 162% at 14 kg), but the predicted Cmax is below the safety threshold of 750 ng/mL, calculated based on an 80% chance to observe a negative TQT trial. However, how this threshold was derived was not understood. At D195, the MAH clarified how the safety threshold was derived and showed that the safety threshold would be 431 ng/mL for females and 1028 ng/mL for males. The upper limit of the 90% prediction interval of Cmax of paediatric patients with a bodyweight of 14 kg exceeds the safety threshold when the most conservative safety threshold of 431 ng/mL is assumed. As RPV is administered as 2.5 mg dispersible tablets to paediatric patients within this weight range, a lower dosing regimen could be considered for these paediatric patients which does not exceed the safety threshold. At D195, the MAH provided additional simulations for Cmax and AUC after administration of 10.0 mg RPV. Even though the Cmax is lowered to a concentration that would be preferred, the AUC decreases to an extent that raises uncertainties for the efficacy of RPV as the 5th % prediction interval for AUCss would decrease from 1595 ng.h/mL (12.5 mg) to 1276 ng.h/mL (10 mg) and would drop substantially below the 80% of the target exposure of the predicted adult geometric mean AUC0-24h,ss (i.e., 1666 ng.h/mL). Therefore, even if there would be a small risk of a positive QTc with the dosing regimen of 12.5 mg RPV, this risk outweighs the risk of underexposure. Underexposure results in resistance development which is a critical issue in the use of HIV drugs. Furthermore, the cut-off of 431 ng/mL is considered conservative since it was derived in female subjects whereas the threshold in male subjects was higher (1028 ng/mL), which further decreases the risk of a positive QTc trial at the current dose in paediatric patients. Altogether, the proposed RPV posology in paediatric patients, the use of 12.5 mg in paediatrics weighing ≥ 14 kg to &lt;20 kg kg weight groups, is considered appropriate.

Furthermore, as no paediatric patients below 16.2 kg were included in study HTX2002 , RPV exposures in this weight group were simulated based on additional modelling and simulation. The simulated 95 th % PI of Cmax for paediatric patients of 10 years old was 611 ng/mL, and thus exceeds the safety threshold, which supports to increase the lower weight limit of 'at least 10 kg'. Moreover, increasing the lower weight limit to ≥ 14 kg would align with the corresponding WHO weight band for ARVs (ie, 14 to &lt;20 kg) and better reflects the paediatric population included in study HTX2002 .

## Children weighing ≥20 to &lt;25 kg

The estimated PK parameters indicate that plasma exposure is 30-50% higher in paediatric patients weighing ≥20 to &lt;25 kg compared to adult patients. This is acceptable given that this risk outweighs the risk of underexposure.

<div style=\"page-break-after: always\"></div>

## Children weighing ≥25 to &lt;40 kg

The population PK analysis showed that RPV exposures in paediatrics weighing ≥25 to &lt;40 kg exceeds the 150% target exposure boundary, which is, according to the Applicant, not of concern as the 90% prediction interval of Cmax,ss was below the previously derived safety threshold of 750 ng/mL that was established using data from studies TMC278-C131 and TMC278-C152 . QT prolongation versus exposure simulations indicated that when assuming a 80% or 90% chance to observe a negative TQT trial, individual simulated Cmax threshold of approximately 750 ng/mL and 618 ng/mL, respectively, were simulated. The MAH was requested to elaborate on the possible effect of the higher exposure in paediatric patients in the weight range of ≥25 to &lt;40 kg and clarify how this 750 ng/mL safety threshold was established. The MAH showed that concentrations in paediatric patients in the weight range of ≥25 to &lt;40 kg, with the highest concentration of approximately 315 ng/mL, do not exceed the most conservative safety threshold of 431 ng/mL. As such, the proposed posology was acceptable to the CHMP.

## 3.4. Unfavourable effects

The safety profile of rilpivirine is well-established in adults and adolescents, and given that exposure is comparable, it is not expected to be substantially different in a paediatric setting. The safety assessment of study C213 Cohort 2 and HTX2002 did not give rise to new safety concerns.

Treatment-emergent RPV RAMs were reported in 5 participants in study C213 Cohort 2.

There were 2 reports of QT-prolongation, 1 in each study. Both events were considered to be not related to the study medication by the investigator.

No evidence of adrenal insufficiency was observed based on basal serum cortisol measurements and/or on serum cortisol values after ACTH stimulation. No signs or symptoms of adrenal insufficiency were identified.

## 3.5. Uncertainties and limitations about unfavourable effects

The rilpivirine paediatric study programme is not powered to generate a comprehensive safety database in children and in the data currently presented, no control arm is available for comparison. Rather, given that exposure is comparable, safety will be extrapolated through a PK/PD-bridge which is in line with EMA guidance. However, plasma exposures are observed to be increased in paediatric patients in all weight categories (i.e. ≥ 10 to &lt;20 kg, ≥ 20  to &lt;25 kg, and ≥ 25 kg) compared to adult patients. The impact of this observation is currently unknown.

Development of resistance-associated mutations (RAMs) to RPV is seen. In the submitted studies, treatment emergent RPV RAMs were reported in 5 participants (all in study C213 Cohort 2). One of these participants was reported with virologic failure (ie, lack or loss of virologic response), 3 participants met suspected virologic failure criteria only, and 1 participant did not meet (suspected) virologic failure criteria. The development of RAMs can have an impact on future treatment options; clarifications are provided in the PI accordingly.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 20: Effects Table

| Effect                                             | Short Description                                                                     | Unit                 | Treatment: Rilpivirine                                                                                  | Uncertainties/ Strength of evidence                                                                                                                                                                                      | References                                |
|----------------------------------------------------|---------------------------------------------------------------------------------------|----------------------|---------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Favourable Effects                                 | Favourable Effects                                                                    | Favourable Effects   | Favourable Effects                                                                                      | Favourable Effects                                                                                                                                                                                                       | Favourable Effects                        |
| Plasma exposure (ratio compared to adults (range)) | AUC 24h,ss                                                                            | ng.h/mL              | >10 to ≤20 kg: 1.5/1 (0.9/1 - 2.1/1) ≥20 to <25 kg: 1.3/1 (0.9/1 - 1.8/1) ≥25 kg: 1.3/1 (0.7/1 - 1.8/1) | Plasma exposures paediatrics are increased compared to adults. Especially for paediatrics weighing <16 kg and ≥25 to <40 kg, where mean simulatedpredicted exposures exceed the 150% target exposure boundary of adults. | Final population PK model                 |
| Virologic response                                 | Proportion of patients with confirmed viral load < 50 HIV -1 RNA copies/ml at week 48 | n/N (%)              | 13/18 (72%)                                                                                             | Relatively small sample size (n=44 patients)                                                                                                                                                                             | Study TMC278-C213 Cohort 2, Study HTX2002 |
| Virologic response                                 | Proportion of patients who remained virologically supressed at week 24                | n/N (%)              | 26/26 (100%)                                                                                            | Relatively small sample size (n=44 patients)                                                                                                                                                                             | Study TMC278-C213 Cohort 2, Study HTX2002 |
| Unfavourable Effects                               | Unfavourable Effects                                                                  | Unfavourable Effects | Unfavourable Effects                                                                                    | Unfavourable Effects                                                                                                                                                                                                     | Unfavourable Effects                      |
| RAM                                                | Incidence of treatment- emergent RAMs                                                 | n/N (%)              | 5/18 (28%)                                                                                              | Relatively small sample size                                                                                                                                                                                             | Study TMC278-C213 Cohort 2                |

Abbreviations: n= number of observations; N= number of subjects in the study (intention - to treat); RAMs: resistance associated mutations

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The extrapolation of efficacy and safety from adults to paediatric patients is in accordance with regulatory practice in the field of HIV. The PD target is expected to respond in the same manner to similar plasma concentrations of the HIV antivirals in both adult and paediatric patients.

RPV plasma exposures in paediatrics are found to be higher compared to adults. In paediatric patients weighing ≤16 kg, RPV exposures are only simulated and are exceeding the 150% target exposure boundary of simulated adult exposure. Also, in paediatric patient s weighing &gt;25 kg to ≤40 kg, RPV exposures exceeds 150% of target exposure of adults.

The safety profile is well-established in adults and adolescents. The safety experience from study C213 Cohort 2 and HTX2002 is limited but does not give rise to new safety concerns. The development of resistance mutations is important, as these may also have an impact on future ARV treatment options.

<div style=\"page-break-after: always\"></div>

Moreover, as the target population are growing children, potential effects on growth or (pubertal) development are also of importance.

## 3.7.2. Balance of benefits and risks

The overall data presented support the efficacy and safety for an extension of the therapeutic indication of Edurant. However, the initially proposed lower age and weight cut-off (2 years and 10 kg) for the dispersible tablets are not supported by data, as the actual enrolled population in the clinical studies was comprised of children 6 years of age and older with a body weight of 16 kg and higher. As no PK, efficacy, or safety data were available in paediatrics below 6 years old and/or 16 kg, RPV exposure is simulated using the population PK model. Additionally, these simulations indicate that plasma exposure exceeds the 150% of the predicted adult target exposure range. The MAH argues that the upper limit of the 90% prediction interval of Cmax (i.e., 460 ng/mL at 14 kg) is below the safety threshold of 750 ng/mL, calculated based on a 80% chance to observe a negative TQT trial. However, how this threshold was derived was not understood. At D195, the MAH clarified how the safety threshold was derived and showed that the safety threshold would be 431 ng/mL for females and 1028 ng/mL for males.  At D195, the MAH provided additional simulations for Cmax and AUC after administration of 10.0 mg RPV. Even though the Cmax is lowered to a concentration that would be preferred, the AUC decreases to an extent that raises uncertainties for the efficacy of RPV as the 5th % prediction interval for AUCss would decrease from 1595 ng.h/mL (12.5 mg) to 1276 ng.h/mL (10 mg) and would drop substantially below the 80% of the target exposure of the predicted adult geometric mean AUC0-24h,ss (i.e., 1666 ng.h/mL). Therefore, even if there would be a small risk of a positive QTc with the dosing regimen of 12.5 mg RPV, this risk outweighs the risk of underexposure. Underexposure results in resistance development which is a critical issue in the use of HIV drugs. Furthermore, the cut-off of 431 ng/mL is considered conservative since it was derived in female subjects whereas the threshold in male subjects was higher (1028 ng/mL), which further decreases the risk of a positive QTc trial at the current dose in paediatric patients. Altogether, the proposed RPV posology in paediatric patients, the use of 12.5 mg in paediatrics weighing ≥ 14 kg to &lt;20 kg weight groups, is considered appropriate.

In addition, the exposure AUC24h,ss of paediatric patients ≥25 to &lt;40 kg exceeds the 150% target exposure boundary. Nevertheless, assuming the most conservative safety threshold of 431 ng/mL, the RPV exposure in these paediatric patients does not exceed the safety threshold.

Further, the MAH is claiming an additional indication for Edurant for treatment of virologically suppressed (HIV-1 RNA less than 50 copies per mL) paediatric patients less than 12 years of age. This was agreed - after adding that patients should not have known or suspected resistance to any nonnucleoside reverse transcriptase inhibitor. However, the MAH was requested to not limit this to paediatric patients less than 12 years of age but reword the therapeutic indication to a combined indication including both treatment naïve as well as treatment experienced paediatric, adolescent and adult patients rather than 2 separate indications. Also considering that RPV has been approved for use in adults who are virologically-suppressed (HIV1 RNA &lt;50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor, as part of the fixed-dose combination product Juluca (RPV+DTG). Also, the fixed dose combinations Odefsey and Eviplera (RPV+FTC+TAF/TDF) can be used in treatment experienced adults and adolescents aged 12 years of age and older.

<div style=\"page-break-after: always\"></div>

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8. Conclusions

The overall benefit/risk balance of Edurant is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality and safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of, Edurant 2.5 mg dispersible tablet  is favourable in the following indication:

Extension application to introduce a new pharmaceutical form associated with new strength (2.5 mg dispersible tablets). The new presentation ,in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients 2 to less than 18 years of age and weighing at least 14 kg to less than 25 kg without known mutations associated with resistance to the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml (see sections 4.4 and 5.1). Genotypic resistance testing should guide the use of EDURANT (see sections 4.4 and 5.1).The PI and RMP have been updated in accordance.

Type II variation (C.I.6.a) to modify the approved therapeutic indication of the already authorised 25 mg film-coated tablets presentation for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and paediatric patients weighing at least 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml   in combination with other antiretroviral medicinal products. (see sections 4.4 and 5.1). Genotypic resistance testing should guide the use of EDURANT (see sections 4.4 and 5.1). This is based on final results from study studies TMC278-TiDP38-C213 Cohort 2. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.4 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. The updated RMP version 10.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes including Annex II and the list of local representatives in the Package Leaflet.

The CHMP therefore recommends the extension(s) of the marketing authorisation for Edurant subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set

<div style=\"page-break-after: always\"></div>

out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Paediatric Data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0101/2022 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.